{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 6057, "items": [{"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:43:13Z", "timestamp": 1574134993724}, "reference-count": 37, "publisher": "American Society for Biochemistry & Molecular Biology (ASBMB)", "issue": "33", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Biol. Chem."], "published-print": {"date-parts": [[2002, 8, 16]]}, "DOI": "10.1074/jbc.m200513200", "type": "journal-article", "created": {"date-parts": [[2002, 9, 18]], "date-time": "2002-09-18T17:58:01Z", "timestamp": 1032371881000}, "page": "29550-29554", "source": "Crossref", "is-referenced-by-count": 15, "title": ["The Large Subunit of Replication Factor C Interacts with the Histone Deacetylase, HDAC1"], "prefix": "10.1074", "volume": "277", "author": [{"given": "Lisa A.", "family": "Anderson", "sequence": "first", "affiliation": []}, {"given": "Neil D.", "family": "Perkins", "sequence": "additional", "affiliation": []}], "member": "28", "published-online": {"date-parts": [[2002, 6, 3]]}, "reference": [{"key": "2019061903151255000_277.33.29550.1", "DOI": "10.1016/S0092-8674(00)81530-5", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.2", "DOI": "10.1016/S0968-0004(99)01516-9", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.3", "DOI": "10.1128/MCB.20.6.1899-1910.2000", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.4", "DOI": "10.1074/jbc.274.33.23027", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.5", "DOI": "10.1074/jbc.M011556200", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.6", "DOI": "10.1038/10640", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.7", "DOI": "10.1038/47412", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.8", "DOI": "10.1016/S0955-0674(00)00200-3", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.9", "DOI": "10.1016/S0092-8674(00)80521-8", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.10", "DOI": "10.1016/S0960-9822(06)00296-X", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.11", "DOI": "10.1126/science.293.5532.1133", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.12", "DOI": "10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.13", "DOI": "10.1016/S0959-437X(99)80006-9", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.14", "DOI": "10.1073/pnas.96.9.4983", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.15", "DOI": "10.1074/jbc.274.44.31127", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.16", "DOI": "10.1016/S0092-8674(00)81326-4", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.17", "DOI": "10.1016/S0092-8674(00)80164-6", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.18", "DOI": "10.1074/jbc.275.13.9797", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.19", "DOI": "10.1128/MCB.16.11.6149", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.20", "author": "Mossi", "volume": "254", "first-page": "209", "year": "1998", "journal-title": "Eur. J. Biochem."}, {"key": "2019061903151255000_277.33.29550.21", "DOI": "10.1016/S0092-8674(00)80661-3", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.22", "author": "Wang", "volume": "14", "first-page": "927", "year": "2000", "journal-title": "Genes Dev."}, {"key": "2019061903151255000_277.33.29550.23", "DOI": "10.1016/S1097-2765(01)00217-9", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.24", "DOI": "10.1101/gad.813200", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.25", "DOI": "10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.26", "DOI": "10.1074/jbc.M010912200", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.27", "DOI": "10.1128/MCB.20.8.2676-2686.2000", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.28", "DOI": "10.1128/MCB.19.5.3485", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.29", "DOI": "10.1016/0076-6879(83)01039-3", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.30", "DOI": "10.1074/jbc.275.7.4719", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.31", "DOI": "10.1006/abio.1993.1170", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.32", "DOI": "10.1126/science.272.5260.408", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.33", "DOI": "10.1073/pnas.89.15.6958", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.34", "author": "Yoshida", "volume": "265", "first-page": "17174", "year": "1990", "journal-title": "J. Biol. Chem."}, {"key": "2019061903151255000_277.33.29550.35", "DOI": "10.1093/emboj/16.21.6346", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.36", "DOI": "10.1093/emboj/17.13.3786", "doi-asserted-by": "publisher"}, {"key": "2019061903151255000_277.33.29550.37", "DOI": "10.1128/MCB.19.10.6632", "doi-asserted-by": "publisher"}], "container-title": ["Journal of Biological Chemistry"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1074/jbc.M200513200", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 19]], "date-time": "2019-06-19T10:16:08Z", "timestamp": 1560939368000}, "score": 64.03754, "issued": {"date-parts": [[2002, 6, 3]]}, "references-count": 37, "journal-issue": {"published-online": {"date-parts": [[2002, 8, 9]]}, "published-print": {"date-parts": [[2002, 8, 16]]}, "issue": "33"}, "alternative-id": ["10.1074/jbc.M200513200"], "URL": "http://dx.doi.org/10.1074/jbc.m200513200", "relation": {"cites": []}, "ISSN": ["0021-9258", "1083-351X"], "issn-type": [{"value": "0021-9258", "type": "print"}, {"value": "1083-351X", "type": "electronic"}]}, {"institution": {"name": "bioRxiv", "place": ["-"], "acronym": ["-"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:47:20Z", "timestamp": 1574891240445}, "posted": {"date-parts": [[2019, 6, 13]]}, "group-title": "Genomics", "reference-count": 37, "publisher": "Cold Spring Harbor Laboratory", "content-domain": {"domain": [], "crossmark-restriction": false}, "accepted": {"date-parts": [[2019, 6, 13]]}, "abstract": "<jats:title>Abstract</jats:title><jats:p>Despite the rapid development of CRISPR/Cas9-mediated gene editing technology, the gene editing potential of CRISPR/Cas9 is hampered by low efficiency, especially for clinical applications. One of the major challenges is that chromatin compaction inevitably limits the Cas9 protein access to the target DNA. However, chromatin compaction is precisely regulated by histone acetylation and deacetylation. To overcome these challenges, we have comprehensively assessed the impacts of histone modifiers such as HDAC (1-9) inhibitors and HAT (p300/CBP, Tip60 and MOZ) inhibitors, on CRISPR/Cas9 mediated gene editing efficiency. Our findings demonstrate that attenuation of HDAC1, HDAC2 activity, but not other HDACs, enhances CRISPR/Cas9-mediated gene knockout frequencies by NHEJ as well as gene knock-in by HDR. Conversely, inhibition of HDAC3 decreases gene editing frequencies. Furthermore, our study showed that attenuation of HDAC1, HDAC2 activity leads to an open chromatin state, facilitates Cas9 access and binding to the targeted DNA and increases the gene editing frequencies. This approach can be applied to other nucleases, such as ZFN and TALEN.</jats:p>", "DOI": "10.1101/670554", "type": "posted-content", "created": {"date-parts": [[2019, 6, 14]], "date-time": "2019-06-14T01:25:25Z", "timestamp": 1560475525000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Inhibition of Histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing"], "prefix": "10.1101", "author": [{"ORCID": "http://orcid.org/0000-0002-3168-8456", "authenticated-orcid": false, "given": "Bin", "family": "Liu", "sequence": "first", "affiliation": []}, {"given": "Siwei", "family": "Chen", "sequence": "additional", "affiliation": []}, {"given": "Anouk La", "family": "Rose", "sequence": "additional", "affiliation": []}, {"given": "Deng", "family": "Chen", "sequence": "additional", "affiliation": []}, {"given": "Fangyuan", "family": "Cao", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "Kiemel", "sequence": "additional", "affiliation": []}, {"given": "Manon", "family": "A\u00efssi", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0001-7217-9300", "authenticated-orcid": false, "given": "FJ", "family": "Dekker", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0003-3997-9052", "authenticated-orcid": false, "given": "HJ", "family": "Haisma", "sequence": "additional", "affiliation": []}], "member": "246", "reference": [{"key": "2019061513250315000_670554v1.1", "DOI": "10.1126/science.1232033", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.2", "DOI": "10.1016/j.drudis.2019.02.011", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.3", "DOI": "10.1016/j.cell.2013.08.021", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.4", "volume": "46", "first-page": "792", "year": "2018", "article-title": "Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs", "journal-title": "Nucleic Acids Res", "DOI": "10.1093/nar/gkx1199", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.5", "DOI": "10.1038/nbt.2808", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.6", "DOI": "10.1038/nmeth.2600", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.7", "DOI": "10.1038/nature24049", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.8", "DOI": "10.1126/science.aaf5573", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.9", "DOI": "10.1073/pnas.1810062115", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.10", "DOI": "10.1093/nar/gkw524", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.11", "volume": "13", "first-page": "e0196238", "year": "2018", "article-title": "Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio", "journal-title": "PLoS One", "DOI": "10.1371/journal.pone.0196238", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.12", "unstructured": "Isaac, R. S. et al. Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. Elife 5, (2016).", "DOI": "10.7554/eLife.13450", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.13", "DOI": "10.1016/j.copbio.2018.07.005", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.14", "DOI": "10.1093/nar/gkv993", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.15", "volume": "8", "first-page": "15315", "year": "2017", "article-title": "Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC", "journal-title": "Nat. Commun", "DOI": "10.1038/ncomms15315", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.16", "DOI": "10.1038/nbt.3199", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.17", "DOI": "10.1016/j.drudis.2009.06.008", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.18", "volume": "4", "first-page": "5105", "year": "2014", "article-title": "Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells", "journal-title": "Sci. Rep"}, {"key": "2019061513250315000_670554v1.19", "volume": "24", "first-page": "939", "year": "2018", "article-title": "p53 inhibits CRISPR\u2013Cas9 engineering in human pluripotent stem cells", "journal-title": "Nat. Med", "DOI": "10.1038/s41591-018-0050-6", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.20", "DOI": "10.1038/s41591-018-0049-z", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.21", "DOI": "10.1016/j.ejmech.2019.05.038", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.22", "DOI": "10.1016/j.virol.2004.01.007", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.23", "volume": "16", "first-page": "141", "year": "2019", "article-title": "The Chromatin Structure of CRISPR-Cas9 Target DNA Controls the Balance between Mutagenic and Homology-Directed Gene-Editing Events", "journal-title": "Mol. Ther. - Nucleic Acids", "DOI": "10.1016/j.omtn.2019.02.009", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.24", "volume": "7", "first-page": "720", "year": "2017", "article-title": "Nanodiamonds as multi-purpose labels for microscopy", "journal-title": "Sci. Rep", "DOI": "10.1038/s41598-017-00797-2", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.25", "volume": "15", "first-page": "1", "year": "2013", "article-title": "Development of an AdEasy-based system to produce first-and second-generation adenoviral vectors with tropism for CAR-or CD46-positive cells", "journal-title": "J. Gene Med", "DOI": "10.1002/jgm.2687", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.26", "DOI": "10.1038/nmeth.3075", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.27", "DOI": "10.1038/sj.gt.3301515", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.28", "volume": "8", "first-page": "558", "year": "2017", "article-title": "The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies", "journal-title": "Mol. Ther. Nucleic Acids", "DOI": "10.1016/j.omtn.2017.08.005", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.29", "unstructured": "Isaac, R. S. et al. Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. Elife 5, (2016).", "DOI": "10.7554/eLife.13450", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.30", "DOI": "10.1073/pnas.1810062115", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.31", "DOI": "10.1038/nbt.3481", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.32", "DOI": "10.1016/j.dnarep.2008.06.018", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.33", "DOI": "10.1089/hum.2013.211", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.34", "volume": "177", "first-page": "1067", "year": "2019", "article-title": "A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9", "journal-title": "Cell", "DOI": "10.1016/j.cell.2019.04.009", "doi-asserted-by": "crossref"}, {"key": "2019061513250315000_670554v1.35", "DOI": "10.1038/sj.onc.1209473", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.36", "DOI": "10.1074/jbc.M105993200", "doi-asserted-by": "publisher"}, {"key": "2019061513250315000_670554v1.37", "DOI": "10.1371/journal.pone.0068915", "doi-asserted-by": "publisher"}], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1101/670554", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 15]], "date-time": "2019-06-15T20:25:18Z", "timestamp": 1560630318000}, "score": 30.115034, "issued": {"date-parts": [[2019, 6, 13]]}, "references-count": 37, "URL": "http://dx.doi.org/10.1101/670554", "relation": {"cites": []}, "subtype": "preprint"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T07:35:53Z", "timestamp": 1574148953952}, "reference-count": 0, "publisher": "American Society for Microbiology", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular and Cellular Biology"], "published-print": {"date-parts": [[2003, 1, 15]]}, "DOI": "10.1128/mcb.23.2.721-732.2003", "type": "journal-article", "created": {"date-parts": [[2003, 1, 1]], "date-time": "2003-01-01T03:57:47Z", "timestamp": 1041393467000}, "page": "721-732", "source": "Crossref", "is-referenced-by-count": 16, "title": ["Regulation of RelA (p65) Function by the Large Subunit of Replication Factor C"], "prefix": "10.1128", "volume": "23", "author": [{"given": "L. A.", "family": "Anderson", "sequence": "first", "affiliation": []}, {"given": "N. D.", "family": "Perkins", "sequence": "additional", "affiliation": []}], "member": "235", "container-title": ["Molecular and Cellular Biology"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1128/MCB.23.2.721-732.2003", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T07:39:45Z", "timestamp": 1482478785000}, "score": 29.513437, "issued": {"date-parts": [[2003, 1, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2003, 1, 15]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1128/mcb.23.2.721-732.2003", "ISSN": ["0270-7306"], "issn-type": [{"value": "0270-7306", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T01:57:28Z", "timestamp": 1575424648353}, "reference-count": 17, "publisher": "Informa UK Limited", "issue": "sup4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Chemotherapy"], "published-print": {"date-parts": [[2004, 11]]}, "DOI": "10.1179/joc.2004.16.supplement-1.64", "type": "journal-article", "created": {"date-parts": [[2014, 1, 9]], "date-time": "2014-01-09T19:22:05Z", "timestamp": 1389295325000}, "page": "64-67", "source": "Crossref", "is-referenced-by-count": 15, "title": ["Histone Deacetylase Inhibitors and Cancer Therapy"], "prefix": "10.1080", "volume": "16", "author": [{"given": "N.B.", "family": "La thangue", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2013, 12, 13]]}, "reference": [{"key": "CIT0001", "DOI": "10.1126/science.1063127", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1042/bj20021321", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1073/pnas.1934713100", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "author": "Kelly WK", "volume": "9", "first-page": "3578", "year": "2003", "volume-title": "Phase I clini-cal trial of histone deacetylase inhibitors: suberoylanilide hydroxamic acid administered intravenously. Clin Can Res"}, {"key": "CIT0005", "DOI": "10.2174/0929867023369763", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "author": "Sandor V", "volume": "8", "first-page": "718", "year": "2002", "journal-title": "Clin Cancer Res"}, {"key": "CIT0007", "author": "Saito A", "volume": "96", "first-page": "4592", "year": "1999", "journal-title": "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumors. Proc Natl Acad Sci"}, {"key": "CIT0008", "DOI": "10.1023/A:1006489328324", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1016/S1359-6446(03)02792-2", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "author": "Chan HM", "volume": "2001", "first-page": "11", "journal-title": "J Cell Sci"}, {"key": "CIT0011", "DOI": "10.4161/cbt.2.2.349", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "author": "Yu C", "volume": "2003", "first-page": "63", "journal-title": "Cancer Res"}, {"key": "CIT0013", "DOI": "10.1182/blood-2002-08-2675", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1038/sj.onc.1207315", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.2174/1568011033482440", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1124/jpet.103.055541", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "author": "Furumai R", "volume": "62", "first-page": "4616", "year": "2002", "journal-title": "FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res"}], "container-title": ["Journal of Chemotherapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 14]], "date-time": "2016-12-14T12:09:51Z", "timestamp": 1481717391000}, "score": 26.052452, "issued": {"date-parts": [[2004, 11]]}, "references-count": 17, "journal-issue": {"published-online": {"date-parts": [[2013, 12, 13]]}, "published-print": {"date-parts": [[2004, 11]]}, "issue": "sup4"}, "alternative-id": ["10.1179/joc.2004.16.Supplement-1.64"], "URL": "http://dx.doi.org/10.1179/joc.2004.16.supplement-1.64", "relation": {"cites": []}, "ISSN": ["1120-009X", "1973-9478"], "issn-type": [{"value": "1120-009X", "type": "print"}, {"value": "1973-9478", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Oncology", "Pharmacology", "Infectious Diseases"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:15:12Z", "timestamp": 1574133312833}, "reference-count": 46, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2004, 9, 1]], "date-time": "2004-09-01T00:00:00Z", "timestamp": 1093996800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Biochemical Pharmacology"], "published-print": {"date-parts": [[2004, 9]]}, "DOI": "10.1016/j.bcp.2004.05.034", "type": "journal-article", "created": {"date-parts": [[2004, 7, 27]], "date-time": "2004-07-27T21:39:26Z", "timestamp": 1090964366000}, "page": "1139-1144", "source": "Crossref", "is-referenced-by-count": 97, "title": ["Histone deacetylase inhibitors open new doors in cancer therapy"], "prefix": "10.1016", "volume": "68", "author": [{"given": "Fiona", "family": "McLaughlin", "sequence": "first", "affiliation": []}, {"given": "Nicholas B", "family": "La Thangue", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Biochemical Pharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0006295204003697?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0006295204003697?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 8]], "date-time": "2019-02-08T13:21:54Z", "timestamp": 1549632114000}, "score": 24.737877, "issued": {"date-parts": [[2004, 9]]}, "references-count": 46, "journal-issue": {"published-print": {"date-parts": [[2004, 9]]}, "issue": "6"}, "alternative-id": ["S0006295204003697"], "URL": "http://dx.doi.org/10.1016/j.bcp.2004.05.034", "ISSN": ["0006-2952"], "issn-type": [{"value": "0006-2952", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T13:34:01Z", "timestamp": 1575552841378}, "reference-count": 54, "publisher": "Oxford University Press (OUP)", "license": [{"URL": "http://creativecommons.org/licenses/by-nc/4.0/", "start": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T00:00:00Z", "timestamp": 1575417600000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"DOI": "10.13039/501100001721", "name": "Rijksuniversiteit Groningen", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Despite the rapid development of CRISPR/Cas9-mediated gene editing technology, the gene editing potential of CRISPR/Cas9 is hampered by low efficiency, especially for clinical applications. One of the major challenges is that chromatin compaction inevitably limits the Cas9 protein access to the target DNA. However, chromatin compaction is precisely regulated by histone acetylation and deacetylation. To overcome these challenges, we have comprehensively assessed the impacts of histone modifiers such as HDAC (1\u20139) inhibitors and HAT (p300/CBP, Tip60 and MOZ) inhibitors, on CRISPR/Cas9 mediated gene editing efficiency. Our findings demonstrate that attenuation of HDAC1, HDAC2 activity, but not other HDACs, enhances CRISPR/Cas9-mediated gene knockout frequencies by NHEJ as well as gene knock-in by HDR. Conversely, inhibition of HDAC3 decreases gene editing frequencies. Furthermore, our study showed that attenuation of HDAC1, HDAC2 activity leads to an open chromatin state, facilitates Cas9 access and binding to the targeted DNA and increases the gene editing frequencies. This approach can be applied to other nucleases, such as ZFN and TALEN.</jats:p>", "DOI": "10.1093/nar/gkz1136", "type": "journal-article", "created": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T20:10:42Z", "timestamp": 1574367042000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing"], "prefix": "10.1093", "author": [{"ORCID": "http://orcid.org/0000-0002-3168-8456", "authenticated-orcid": false, "given": "Bin", "family": "Liu", "sequence": "first", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Siwei", "family": "Chen", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Anouk La", "family": "Rose", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Deng", "family": "Chen", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Fangyuan", "family": "Cao", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Martijn", "family": "Zwinderman", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Dominik", "family": "Kiemel", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}, {"name": "Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, 69120, Germany"}]}, {"given": "Manon", "family": "A\u00efssi", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Frank J", "family": "Dekker", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}, {"given": "Hidde J", "family": "Haisma", "sequence": "additional", "affiliation": [{"name": "Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands"}]}], "member": "286", "published-online": {"date-parts": [[2019, 12, 4]]}, "reference": [{"key": "2019120405005410900_B1", "doi-asserted-by": "crossref", "first-page": "475", "DOI": "10.1146/annurev.micro.112408.134123", "article-title": "CRISPR/Cas system and its role in phage-bacteria interactions", "volume": "64", "author": "Deveau", "year": "2010", "journal-title": "Annu. Rev. Microbiol."}, {"key": "2019120405005410900_B2", "doi-asserted-by": "crossref", "first-page": "167", "DOI": "10.1126/science.1179555", "article-title": "CRISPR/Cas, the immune system of bacteria and archaea", "volume": "327", "author": "Horvath", "year": "2010", "journal-title": "Science"}, {"key": "2019120405005410900_B3", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1146/annurev-genet-110410-132430", "article-title": "CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation", "volume": "45", "author": "Bhaya", "year": "2011", "journal-title": "Annu. Rev. Genet."}, {"key": "2019120405005410900_B4", "doi-asserted-by": "crossref", "first-page": "816", "DOI": "10.1126/science.1225829", "article-title": "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", "volume": "337", "author": "Jinek", "year": "2012", "journal-title": "Science"}, {"key": "2019120405005410900_B5", "doi-asserted-by": "crossref", "first-page": "819", "DOI": "10.1126/science.1231143", "article-title": "Multiplex genome engineering using CRISPR/Cas systems", "volume": "339", "author": "Cong", "year": "2013", "journal-title": "Science"}, {"key": "2019120405005410900_B6", "doi-asserted-by": "crossref", "first-page": "251", "DOI": "10.1038/38444", "article-title": "Crystal structure of the nucleosome core particle at 2.8 A resolution", "volume": "389", "author": "Luger", "year": "1997", "journal-title": "Nature"}, {"key": "2019120405005410900_B7", "doi-asserted-by": "crossref", "first-page": "823", "DOI": "10.1126/science.1232033", "article-title": "RNA-guided human genome engineering via Cas9", "volume": "339", "author": "Mali", "year": "2013", "journal-title": "Science"}, {"key": "2019120405005410900_B8", "doi-asserted-by": "crossref", "first-page": "955", "DOI": "10.1016/j.drudis.2019.02.011", "article-title": "CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment", "volume": "24", "author": "Liu", "year": "2019", "journal-title": "Drug Discov. Today"}, {"key": "2019120405005410900_B9", "doi-asserted-by": "crossref", "first-page": "1380", "DOI": "10.1016/j.cell.2013.08.021", "article-title": "Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity", "volume": "154", "author": "Ran", "year": "2013", "journal-title": "Cell"}, {"key": "2019120405005410900_B10", "doi-asserted-by": "crossref", "first-page": "792", "DOI": "10.1093/nar/gkx1199", "article-title": "Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs", "volume": "46", "author": "Ryan", "year": "2018", "journal-title": "Nucleic Acids Res."}, {"key": "2019120405005410900_B11", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1038/nbt.2808", "article-title": "Improving CRISPR-Cas nuclease specificity using truncated guide RNAs", "volume": "32", "author": "Fu", "year": "2014", "journal-title": "Nat. Biotechnol."}, {"key": "2019120405005410900_B12", "doi-asserted-by": "crossref", "first-page": "973", "DOI": "10.1038/nmeth.2600", "article-title": "RNA-guided gene activation by CRISPR-Cas9-based transcription factors", "volume": "10", "author": "Perez-Pinera", "year": "2013", "journal-title": "Nat. Methods"}, {"key": "2019120405005410900_B13", "doi-asserted-by": "crossref", "first-page": "280", "DOI": "10.1038/nature24049", "article-title": "RNA targeting with CRISPR-Cas13", "volume": "550", "author": "Abudayyeh", "year": "2017", "journal-title": "Nature"}, {"key": "2019120405005410900_B14", "doi-asserted-by": "crossref", "first-page": "aaf5573", "DOI": "10.1126/science.aaf5573", "article-title": "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", "volume": "353", "author": "Abudayyeh", "year": "2016", "journal-title": "Science"}, {"key": "2019120405005410900_B15", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1186/s13059-018-1591-1", "article-title": "NmeCas9 is an intrinsically high-fidelity genome-editing platform", "volume": "19", "author": "Amrani", "year": "2018", "journal-title": "Genome Biol."}, {"key": "2019120405005410900_B16", "doi-asserted-by": "crossref", "first-page": "714", "DOI": "10.1016/j.molcel.2018.12.003", "article-title": "A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing", "volume": "73", "author": "Edraki", "year": "2019", "journal-title": "Mol. Cell"}, {"key": "2019120405005410900_B17", "doi-asserted-by": "crossref", "first-page": "9351", "DOI": "10.1073/pnas.1810062115", "article-title": "Nucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo", "volume": "115", "author": "Yarrington", "year": "2018", "journal-title": "Proc. Natl. Acad. Sci. U.S.A."}, {"key": "2019120405005410900_B18", "doi-asserted-by": "crossref", "first-page": "6482", "DOI": "10.1093/nar/gkw524", "article-title": "Probing the impact of chromatin conformation on genome editing tools", "volume": "44", "author": "Chen", "year": "2016", "journal-title": "Nucleic Acids Res."}, {"key": "2019120405005410900_B19", "doi-asserted-by": "crossref", "first-page": "e0196238", "DOI": "10.1371/journal.pone.0196238", "article-title": "Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio)", "volume": "13", "author": "Uusi-M\u00e4kel\u00e4", "year": "2018", "journal-title": "PLoS One"}, {"key": "2019120405005410900_B20", "doi-asserted-by": "crossref", "first-page": "e13450", "DOI": "10.7554/eLife.13450", "article-title": "Nucleosome breathing and remodeling constrain CRISPR-Cas9 function", "volume": "5", "author": "Isaac", "year": "2016", "journal-title": "Elife"}, {"key": "2019120405005410900_B21", "doi-asserted-by": "crossref", "first-page": "68", "DOI": "10.1016/j.copbio.2018.07.005", "article-title": "The influence of eukaryotic chromatin state on CRISPR\u2013Cas9 editing efficiencies", "volume": "55", "author": "Verkuijl", "year": "2019", "journal-title": "Curr. Opin. Biotechnol."}, {"key": "2019120405005410900_B22", "doi-asserted-by": "crossref", "first-page": "349", "DOI": "10.1038/38664", "article-title": "Histone acetylation in chromatin structure and transcription", "volume": "389", "author": "Grunstein", "year": "1997", "journal-title": "Nature"}, {"key": "2019120405005410900_B23", "doi-asserted-by": "crossref", "first-page": "224", "DOI": "10.1093/embo-reports/kvf053", "article-title": "Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics", "volume": "3", "author": "Eberharter", "year": "2002", "journal-title": "EMBO Rep."}, {"key": "2019120405005410900_B24", "doi-asserted-by": "crossref", "first-page": "9379", "DOI": "10.1093/nar/gkv993", "article-title": "Nuclear domain \u2018knock-in\u2019 screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing", "volume": "43", "author": "Pinder", "year": "2015", "journal-title": "Nucleic Acids Res."}, {"key": "2019120405005410900_B25", "doi-asserted-by": "crossref", "first-page": "15315", "DOI": "10.1038/ncomms15315", "article-title": "Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC", "volume": "8", "author": "Kwon", "year": "2017", "journal-title": "Nat. Commun."}, {"key": "2019120405005410900_B26", "doi-asserted-by": "crossref", "first-page": "510", "DOI": "10.1038/nbt.3199", "article-title": "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers", "volume": "33", "author": "Hilton", "year": "2015", "journal-title": "Nat. Biotechnol."}, {"key": "2019120405005410900_B27", "doi-asserted-by": "crossref", "first-page": "942", "DOI": "10.1016/j.drudis.2009.06.008", "article-title": "Histone acetyl transferases as emerging drug targets", "volume": "14", "author": "Dekker", "year": "2009", "journal-title": "Drug Discov. Today"}, {"key": "2019120405005410900_B28", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1016/j.virol.2004.01.007", "article-title": "Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors", "volume": "321", "author": "Gon\u00e7alves", "year": "2004", "journal-title": "Virology"}, {"key": "2019120405005410900_B29", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/j.omtn.2019.02.009", "article-title": "The chromatin structure of CRISPR-Cas9 target DNA controls the balance between mutagenic and homology-directed gene-editing events", "volume": "16", "author": "Janssen", "year": "2019", "journal-title": "Mol. Ther. - Nucleic Acids"}, {"key": "2019120405005410900_B30", "doi-asserted-by": "crossref", "first-page": "720", "DOI": "10.1038/s41598-017-00797-2", "article-title": "Nanodiamonds as multi-purpose labels for microscopy", "volume": "7", "author": "Hemelaar", "year": "2017", "journal-title": "Sci. Rep."}, {"key": "2019120405005410900_B31", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1016/j.ejmech.2019.05.038", "article-title": "Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages", "volume": "177", "author": "Cao", "year": "2019", "journal-title": "Eur. J. Med. Chem."}, {"key": "2019120405005410900_B32", "doi-asserted-by": "crossref", "first-page": "5105", "DOI": "10.1038/srep05105", "article-title": "Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells", "volume": "4", "author": "Maggio", "year": "2014", "journal-title": "Sci. Rep."}, {"key": "2019120405005410900_B33", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1002/jgm.2687", "article-title": "Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells", "volume": "15", "author": "Janssen", "year": "2013", "journal-title": "J. Gene Med."}, {"key": "2019120405005410900_B34", "doi-asserted-by": "crossref", "first-page": "1051", "DOI": "10.1038/nmeth.3075", "article-title": "Adenoviral vector DNA for accurate genome editing with engineered nucleases", "volume": "11", "author": "Holkers", "year": "2014", "journal-title": "Nat. Methods"}, {"key": "2019120405005410900_B35", "doi-asserted-by": "crossref", "first-page": "1347", "DOI": "10.1038/sj.gt.3301515", "article-title": "CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors", "volume": "8", "author": "Alemany", "year": "2001", "journal-title": "Gene Ther."}, {"key": "2019120405005410900_B36", "doi-asserted-by": "crossref", "first-page": "1473", "DOI": "10.1093/bioinformatics/btu048", "article-title": "Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases", "volume": "30", "author": "Bae", "year": "2014", "journal-title": "Bioinformatics"}, {"key": "2019120405005410900_B37", "doi-asserted-by": "crossref", "first-page": "56", "DOI": "10.1016/j.molcel.2018.06.003", "article-title": "The nucleosome remodeling and deacetylation complex modulates chromatin structure at sites of active transcription to fine-tune gene expression", "volume": "71", "author": "Bornel\u00f6v", "year": "2018", "journal-title": "Mol. Cell"}, {"key": "2019120405005410900_B38", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1007/978-1-61779-477-3_5", "article-title": "Analysis of nucleosome positioning using a nucleosome-scanning assay", "volume": "833", "author": "Infante", "year": "2012", "journal-title": "Methods Mol. Biol."}, {"key": "2019120405005410900_B39", "doi-asserted-by": "crossref", "first-page": "927", "DOI": "10.1038/s41591-018-0049-z", "article-title": "CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response", "volume": "24", "author": "Haapaniemi", "year": "2018", "journal-title": "Nat. Med."}, {"key": "2019120405005410900_B40", "doi-asserted-by": "crossref", "first-page": "R79", "DOI": "10.1186/bcr3192", "article-title": "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat", "volume": "14", "author": "Tate", "year": "2012", "journal-title": "Breast Cancer Res."}, {"key": "2019120405005410900_B41", "author": "Butler", "first-page": "131", "year": "1999", "article-title": "Cell counting and viability measurements", "volume-title": "Animal Cell Biotechnology", "DOI": "10.1385/0-89603-547-6:131", "doi-asserted-by": "crossref"}, {"key": "2019120405005410900_B42", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/j.omtn.2019.02.009", "article-title": "The chromatin structure of CRISPR-Cas9 target DNA controls the balance between mutagenic and homology-directed gene-editing events", "volume": "16", "author": "Janssen", "year": "2019", "journal-title": "Mol. Ther. Nucleic Acids"}, {"key": "2019120405005410900_B43", "doi-asserted-by": "crossref", "first-page": "11485", "DOI": "10.1038/ncomms11485", "article-title": "MNase titration reveals differences between nucleosome occupancy and chromatin accessibility", "volume": "7", "author": "Mieczkowski", "year": "2016", "journal-title": "Nat. Commun."}, {"key": "2019120405005410900_B44", "doi-asserted-by": "crossref", "first-page": "558", "DOI": "10.1016/j.omtn.2017.08.005", "article-title": "The Chromatin Structure Differentially impacts high-specificity CRISPR-Cas9 nuclease strategies", "volume": "8", "author": "Chen", "year": "2017", "journal-title": "Mol. Ther. Nucleic Acids"}, {"key": "2019120405005410900_B45", "doi-asserted-by": "crossref", "first-page": "e3000160", "DOI": "10.1371/journal.pbio.3000160", "article-title": "Correction: Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair", "volume": "17", "author": "PLOS Biology Staff", "year": "2019", "journal-title": "PLoS Biol."}, {"key": "2019120405005410900_B46", "doi-asserted-by": "crossref", "first-page": "339", "DOI": "10.1038/nbt.3481", "article-title": "Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA", "volume": "34", "author": "Richardson", "year": "2016", "journal-title": "Nat. Biotechnol."}, {"key": "2019120405005410900_B47", "doi-asserted-by": "crossref", "first-page": "1765", "DOI": "10.1016/j.dnarep.2008.06.018", "article-title": "Comparison of nonhomologous end joining and homologous recombination in human cells", "volume": "7", "author": "Mao", "year": "2008", "journal-title": "DNA Repair (Amst)."}, {"key": "2019120405005410900_B48", "doi-asserted-by": "crossref", "first-page": "99", "DOI": "10.1038/nsmb.3347", "article-title": "Histone degradation in response to DNA damage enhances chromatin dynamics and recombination rates", "volume": "24", "author": "Hauer", "year": "2017", "journal-title": "Nat. Struct. Mol. Biol."}, {"key": "2019120405005410900_B49", "doi-asserted-by": "crossref", "first-page": "939", "DOI": "10.1038/s41591-018-0050-6", "article-title": "p53 inhibits CRISPR\u2013Cas9 engineering in human pluripotent stem cells", "volume": "24", "author": "Ihry", "year": "2018", "journal-title": "Nat. Med."}, {"key": "2019120405005410900_B50", "doi-asserted-by": "crossref", "first-page": "599", "DOI": "10.1089/hum.2013.211", "article-title": "Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors", "volume": "25", "author": "Joglekar", "year": "2014", "journal-title": "Hum. Gene Ther."}, {"key": "2019120405005410900_B51", "doi-asserted-by": "crossref", "first-page": "1067", "DOI": "10.1016/j.cell.2019.04.009", "article-title": "A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9", "volume": "177", "author": "Maji", "year": "2019", "journal-title": "Cell"}, {"key": "2019120405005410900_B52", "doi-asserted-by": "crossref", "first-page": "4495", "DOI": "10.1038/sj.onc.1209473", "article-title": "Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src", "volume": "25", "author": "Longworth", "year": "2006", "journal-title": "Oncogene"}, {"key": "2019120405005410900_B53", "doi-asserted-by": "crossref", "first-page": "9447", "DOI": "10.1074/jbc.M105993200", "article-title": "Functional domains of histone deacetylase-3", "volume": "277", "author": "Yang", "year": "2002", "journal-title": "J. Biol. Chem."}, {"key": "2019120405005410900_B54", "doi-asserted-by": "crossref", "first-page": "e68915", "DOI": "10.1371/journal.pone.0068915", "article-title": "Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma", "volume": "8", "author": "Wells", "year": "2013", "journal-title": "PLoS One"}], "container-title": ["Nucleic Acids Research"], "language": "en", "link": [{"URL": "http://academic.oup.com/nar/advance-article-pdf/doi/10.1093/nar/gkz1136/31196669/gkz1136.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://academic.oup.com/nar/advance-article-pdf/doi/10.1093/nar/gkz1136/31196669/gkz1136.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T10:01:41Z", "timestamp": 1575453701000}, "score": 23.894, "issued": {"date-parts": [[2019, 12, 4]]}, "references-count": 54, "URL": "http://dx.doi.org/10.1093/nar/gkz1136", "relation": {"cites": []}, "ISSN": ["0305-1048", "1362-4962"], "issn-type": [{"value": "0305-1048", "type": "print"}, {"value": "1362-4962", "type": "electronic"}], "subject": ["Genetics"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T10:36:04Z", "timestamp": 1574505364584}, "reference-count": 0, "publisher": "F1000 Research Ltd", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2003, 4, 2]]}, "DOI": "10.3410/f.1012821.187300", "type": "dataset", "created": {"date-parts": [[2012, 9, 20]], "date-time": "2012-09-20T00:50:55Z", "timestamp": 1348102255000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Faculty of 1000 evaluation for Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway."], "prefix": "10.3410", "author": [{"given": "Albert", "family": "La Spada", "sequence": "first", "affiliation": []}], "member": "2560", "content-created": {"date-parts": [[2003, 4, 1]]}, "container-title": ["F1000 - Post-publication peer review of the biomedical literature"], "deposited": {"date-parts": [[2012, 9, 20]], "date-time": "2012-09-20T00:51:47Z", "timestamp": 1348102307000}, "score": 23.435633, "issued": {"date-parts": [[2003, 4, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.3410/f.1012821.187300"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T13:26:06Z", "timestamp": 1574429166260}, "reference-count": 0, "publisher": "American Chemical Society (ACS)", "issue": "25", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Biochemistry"], "published-print": {"date-parts": [[2010, 6, 29]]}, "DOI": "10.1021/bi100391w", "type": "journal-article", "created": {"date-parts": [[2010, 5, 12]], "date-time": "2010-05-12T14:41:29Z", "timestamp": 1273675289000}, "page": "5244-5257", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Extensive and Varied Modifications in Histone H2B of Wild-Type and Histone Deacetylase 1 MutantNeurospora crassa"], "prefix": "10.1021", "volume": "49", "author": [{"given": "D. C.", "family": "Anderson", "sequence": "first", "affiliation": []}, {"given": "George R.", "family": "Green", "sequence": "additional", "affiliation": []}, {"given": "Kristina", "family": "Smith", "sequence": "additional", "affiliation": []}, {"given": "Eric U.", "family": "Selker", "sequence": "additional", "affiliation": []}], "member": "316", "container-title": ["Biochemistry"], "language": "en", "link": [{"URL": "https://pubs.acs.org/doi/pdf/10.1021/bi100391w", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 30]], "date-time": "2019-09-30T05:49:41Z", "timestamp": 1569822581000}, "score": 22.814274, "issued": {"date-parts": [[2010, 6, 29]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 6, 29]]}, "issue": "25"}, "alternative-id": ["10.1021/bi100391w"], "URL": "http://dx.doi.org/10.1021/bi100391w", "ISSN": ["0006-2960", "1520-4995"], "issn-type": [{"value": "0006-2960", "type": "print"}, {"value": "1520-4995", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T10:44:43Z", "timestamp": 1575197083656}, "reference-count": 48, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2013, 3, 1]], "date-time": "2013-03-01T00:00:00Z", "timestamp": 1362096000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Int J Hematol"], "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.1007/s12185-013-1290-3", "type": "journal-article", "created": {"date-parts": [[2013, 3, 9]], "date-time": "2013-03-09T06:35:19Z", "timestamp": 1362810919000}, "page": "324-332", "source": "Crossref", "is-referenced-by-count": 20, "title": ["Histone deacetylase inhibitors in the treatment for multiple myeloma"], "prefix": "10.1007", "volume": "97", "author": [{"given": "Teru", "family": "Hideshima", "sequence": "first", "affiliation": []}, {"given": "Kenneth C.", "family": "Anderson", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 3, 10]]}, "reference": [{"key": "1290_CR1", "doi-asserted-by": "crossref", "first-page": "R546", "DOI": "10.1016/j.cub.2004.07.007", "volume": "14", "author": "CL Peterson", "year": "2004", "unstructured": "Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol CB. 2004;14:R546\u201351.", "journal-title": "Curr Biol CB"}, {"key": "1290_CR2", "doi-asserted-by": "crossref", "first-page": "286", "DOI": "10.1016/S0168-9525(03)00073-8", "volume": "19", "author": "E Verdin", "year": "2003", "unstructured": "Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286\u201393.", "journal-title": "Trends Genet"}, {"key": "1290_CR3", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1038/nrc1779", "volume": "6", "author": "S Minucci", "year": "2006", "unstructured": "Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.", "journal-title": "Nat Rev Cancer"}, {"key": "1290_CR4", "doi-asserted-by": "crossref", "first-page": "238", "DOI": "10.1038/nchembio.313", "volume": "6", "author": "JE Bradner", "year": "2010", "unstructured": "Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6:238\u201343.", "journal-title": "Nat Chem Biol"}, {"key": "1290_CR5", "doi-asserted-by": "crossref", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540\u20135.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1290_CR6", "doi-asserted-by": "crossref", "first-page": "4609", "DOI": "10.1021/jm030235w", "volume": "46", "author": "SW Remiszewski", "year": "2003", "unstructured": "Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P. N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem. 2003;46:4609\u201324.", "journal-title": "J Med Chem"}, {"key": "1290_CR7", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1158/0008-5472.CAN-03-2043", "volume": "64", "author": "P Atadja", "year": "2004", "unstructured": "Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004;64:689\u201395.", "journal-title": "Cancer Res"}, {"key": "1290_CR8", "doi-asserted-by": "crossref", "first-page": "2615", "DOI": "10.1182/blood-2003-01-0233", "volume": "102", "author": "L Catley", "year": "2003", "unstructured": "Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi N, Schlossman R, Richardson P, Griffin J, Anderson KC. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615\u201322.", "journal-title": "Blood"}, {"key": "1290_CR9", "doi-asserted-by": "crossref", "first-page": "1768", "DOI": "10.1182/blood-2004-09-3413", "volume": "105", "author": "P George", "year": "2005", "unstructured": "George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005;105:1768\u201376.", "journal-title": "Blood"}, {"key": "1290_CR10", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.1182/blood-2005-11-4639", "volume": "108", "author": "W Fiskus", "year": "2006", "unstructured": "Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006;108:645\u201352.", "journal-title": "Blood"}, {"key": "1290_CR11", "doi-asserted-by": "crossref", "first-page": "11298", "DOI": "10.1158/0008-5472.CAN-06-0049", "volume": "66", "author": "L Geng", "year": "2006", "unstructured": "Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66:11298\u2013304.", "journal-title": "Cancer Res"}, {"key": "1290_CR12", "doi-asserted-by": "crossref", "first-page": "1140", "DOI": "10.1158/1078-0432.CCR-06-1751", "volume": "13", "author": "C Yu", "year": "2007", "unstructured": "Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007;13:1140\u20138.", "journal-title": "Clin Cancer Res"}, {"key": "1290_CR13", "doi-asserted-by": "crossref", "first-page": "3441", "DOI": "10.1182/blood-2006-04-016055", "volume": "108", "author": "L Catley", "year": "2006", "unstructured": "Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441\u20139.", "journal-title": "Blood"}, {"key": "1290_CR14", "doi-asserted-by": "crossref", "first-page": "5781", "DOI": "10.1158/0008-5472.CAN-05-4186", "volume": "66", "author": "P Maiso", "year": "2006", "unstructured": "Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66:5781\u20139.", "journal-title": "Cancer Res"}, {"key": "1290_CR15", "first-page": "721", "volume": "2", "author": "JA Plumb", "year": "2003", "unstructured": "Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2:721\u20138.", "journal-title": "Mol Cancer Ther"}, {"key": "1290_CR16", "doi-asserted-by": "crossref", "first-page": "634", "DOI": "10.1158/1078-0432.CCR-05-1132", "volume": "12", "author": "DZ Qian", "year": "2006", "unstructured": "Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634\u201342.", "journal-title": "Clin Cancer Res"}, {"key": "1290_CR17", "doi-asserted-by": "crossref", "first-page": "1207", "DOI": "10.1038/sj.leu.2403388", "volume": "18", "author": "DM Lucas", "year": "2004", "unstructured": "Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004;18:1207\u201314.", "journal-title": "Leukemia"}, {"key": "1290_CR18", "doi-asserted-by": "crossref", "first-page": "784", "DOI": "10.1002/ijc.21069", "volume": "116", "author": "R Sakimura", "year": "2005", "unstructured": "Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y. Antitumor effects of histone deacetylase inhibitor on Ewing\u2019s family tumors. Int J Cancer. 2005;116:784\u201392.", "journal-title": "Int J Cancer"}, {"key": "1290_CR19", "doi-asserted-by": "crossref", "first-page": "711", "DOI": "10.1007/s00280-005-0182-5", "volume": "58", "author": "PA Konstantinopoulos", "year": "2006", "unstructured": "Konstantinopoulos PA, Vandoros GP, Papavassiliou AG. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol. 2006;58:711\u20135.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "1290_CR20", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1007/s10637-006-9000-0", "volume": "25", "author": "Y Kano", "year": "2007", "unstructured": "Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs. 2007;25:31\u201340.", "journal-title": "Invest New Drugs"}, {"key": "1290_CR21", "doi-asserted-by": "crossref", "first-page": "1795", "DOI": "10.1002/ijc.22405", "volume": "120", "author": "JA Karam", "year": "2007", "unstructured": "Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer. 2007;120:1795\u2013802.", "journal-title": "Int J Cancer"}, {"key": "1290_CR22", "doi-asserted-by": "crossref", "first-page": "156", "DOI": "10.1111/j.1365-2141.2004.04882.x", "volume": "125", "author": "SB Khan", "year": "2004", "unstructured": "Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125:156\u201361.", "journal-title": "Br J Haematol"}, {"key": "1290_CR23", "doi-asserted-by": "crossref", "first-page": "2579", "DOI": "10.1182/blood-2011-10-387365", "volume": "119", "author": "L Santo", "year": "2012", "unstructured": "Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579\u201389.", "journal-title": "Blood"}, {"key": "1290_CR24", "doi-asserted-by": "crossref", "first-page": "727", "DOI": "10.1016/S0092-8674(03)00939-5", "volume": "115", "author": "Y Kawaguchi", "year": "2003", "unstructured": "Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727\u201338.", "journal-title": "Cell"}, {"key": "1290_CR25", "doi-asserted-by": "crossref", "first-page": "388", "DOI": "10.1034/j.1600-0854.2002.30602.x", "volume": "3", "author": "R Garcia-Mata", "year": "2002", "unstructured": "Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic. 2002;3:388\u201396.", "journal-title": "Traffic"}, {"key": "1290_CR26", "doi-asserted-by": "crossref", "first-page": "8567", "DOI": "10.1073/pnas.0503221102", "volume": "102", "author": "T Hideshima", "year": "2005", "unstructured": "Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8567\u201372.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1290_CR27", "first-page": "991a", "volume": "108", "author": "R Feng", "year": "2006", "unstructured": "Feng R, Hager JH, Hassig CA, Scranton SA, Payne JE, Mapara MY, Roodman D, Lentzsch S. A novel, mercaptoketone-based HDAC inhibitor, KD5170 exerts marked inhibition of osteoclast formation and anti-myeloma activity in vitro. Blood. 2006;108:991a.", "journal-title": "Blood"}, {"key": "1290_CR28", "doi-asserted-by": "crossref", "first-page": "2289", "DOI": "10.2174/1381612043383980", "volume": "10", "author": "R Piekarz", "year": "2004", "unstructured": "Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 2004;10:2289\u201398.", "journal-title": "Curr Pharm Des"}, {"key": "1290_CR29", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.3727/096504005775082066", "volume": "15", "author": "M Loprevite", "year": "2005", "unstructured": "Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15:39\u201348.", "journal-title": "Oncol Res"}, {"key": "1290_CR30", "doi-asserted-by": "crossref", "first-page": "834", "DOI": "10.1126/science.1175371", "volume": "325", "author": "C Choudhary", "year": "2009", "unstructured": "Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834\u201340.", "journal-title": "Science"}, {"key": "1290_CR31", "doi-asserted-by": "crossref", "first-page": "4055", "DOI": "10.1182/blood-2002-11-3514", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055\u201362.", "journal-title": "Blood"}, {"key": "1290_CR32", "doi-asserted-by": "crossref", "first-page": "646", "DOI": "10.1593/neo.04655", "volume": "7", "author": "TE Fandy", "year": "2005", "unstructured": "Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia. 2005;7:646\u201357.", "journal-title": "Neoplasia"}, {"key": "1290_CR33", "doi-asserted-by": "crossref", "first-page": "1052", "DOI": "10.1158/1541-7786.MCR-11-0587", "volume": "10", "author": "X Chen", "year": "2012", "unstructured": "Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res. 2012;10:1052\u201364.", "journal-title": "Mol Cancer Res"}, {"key": "1290_CR34", "doi-asserted-by": "crossref", "first-page": "406", "DOI": "10.1182/blood-2009-07-235663", "volume": "116", "author": "J Kikuchi", "year": "2010", "unstructured": "Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406\u201317.", "journal-title": "Blood"}, {"key": "1290_CR35", "first-page": "491", "volume": "118", "author": "S Mukherjee", "year": "2008", "unstructured": "Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008;118:491\u2013504.", "journal-title": "J Clin Invest"}, {"key": "1290_CR36", "doi-asserted-by": "crossref", "first-page": "5307", "DOI": "10.1158/0008-5472.CAN-08-4472", "volume": "69", "author": "S Deleu", "year": "2009", "unstructured": "Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69:5307\u201311.", "journal-title": "Cancer Res"}, {"key": "1290_CR37", "first-page": "3578", "volume": "9", "author": "WK Kelly", "year": "2003", "unstructured": "Kelly WK, Richon VM, O\u2019Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:3578\u201388.", "journal-title": "Clin Cancer Res"}, {"key": "1290_CR38", "doi-asserted-by": "crossref", "first-page": "3923", "DOI": "10.1200/JCO.2005.14.167", "volume": "23", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly WK, O\u2019Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923\u201331.", "journal-title": "J Clin Oncol"}, {"key": "1290_CR39", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.3816/CLC.2006.n.003", "volume": "7", "author": "LM Krug", "year": "2006", "unstructured": "Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257\u201361.", "journal-title": "Clin Lung Cancer"}, {"key": "1290_CR40", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "volume": "109", "author": "M Duvic", "year": "2007", "unstructured": "Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31\u20139.", "journal-title": "Blood"}, {"key": "1290_CR41", "doi-asserted-by": "crossref", "first-page": "502", "DOI": "10.1080/10428190701817258", "volume": "49", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502\u20137.", "journal-title": "Leuk Lymphoma"}, {"key": "1290_CR42", "first-page": "718", "volume": "8", "author": "V Sandor", "year": "2002", "unstructured": "Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718\u201328.", "journal-title": "Clin Cancer Res"}, {"key": "1290_CR43", "doi-asserted-by": "crossref", "first-page": "325", "DOI": "10.1046/j.1359-4117.2002.01039.x", "volume": "2", "author": "JL Marshall", "year": "2002", "unstructured": "Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2:325\u201332.", "journal-title": "J Exp Ther Oncol"}, {"key": "1290_CR44", "doi-asserted-by": "crossref", "first-page": "959", "DOI": "10.1182/blood-2004-05-1693", "volume": "105", "author": "JC Byrd", "year": "2005", "unstructured": "Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959\u201367.", "journal-title": "Blood"}, {"key": "1290_CR45", "doi-asserted-by": "crossref", "first-page": "1547", "DOI": "10.1158/1078-0432.CCR-05-1423", "volume": "12", "author": "RW Robey", "year": "2006", "unstructured": "Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res. 2006;12:1547\u201355.", "journal-title": "Clin Cancer Res"}, {"key": "1290_CR46", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.3816/CGC.2006.n.018", "volume": "5", "author": "WM Stadler", "year": "2006", "unstructured": "Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57\u201360.", "journal-title": "Clin Genitourin Cancer"}, {"key": "1290_CR47", "doi-asserted-by": "crossref", "first-page": "336", "DOI": "10.1002/cncr.25584", "volume": "117", "author": "R Niesvizky", "year": "2011", "unstructured": "Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336\u201342.", "journal-title": "Cancer"}, {"key": "1290_CR48", "doi-asserted-by": "crossref", "first-page": "3647", "DOI": "10.1158/0008-5472.CAN-09-3360", "volume": "70", "author": "CJ Lai", "year": "2010", "unstructured": "Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010;70:3647\u201356.", "journal-title": "Cancer Res"}], "container-title": ["International Journal of Hematology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s12185-013-1290-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s12185-013-1290-3/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12185-013-1290-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 10]], "date-time": "2019-07-10T18:33:06Z", "timestamp": 1562783586000}, "score": 22.473385, "issued": {"date-parts": [[2013, 3]]}, "references-count": 48, "journal-issue": {"published-print": {"date-parts": [[2013, 3]]}, "issue": "3"}, "alternative-id": ["1290"], "URL": "http://dx.doi.org/10.1007/s12185-013-1290-3", "relation": {"cites": []}, "ISSN": ["0925-5710", "1865-3774"], "issn-type": [{"value": "0925-5710", "type": "print"}, {"value": "1865-3774", "type": "electronic"}], "subject": ["Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T18:32:42Z", "timestamp": 1575311562906}, "reference-count": 99, "publisher": "Springer Science and Business Media LLC", "issue": "12", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2008, 10, 7]], "date-time": "2008-10-07T00:00:00Z", "timestamp": 1223337600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Clin Oncol"], "published-print": {"date-parts": [[2008, 12]]}, "DOI": "10.1038/ncponc1238", "type": "journal-article", "created": {"date-parts": [[2008, 10, 7]], "date-time": "2008-10-07T09:21:43Z", "timestamp": 1223371303000}, "page": "714-726", "source": "Crossref", "is-referenced-by-count": 57, "title": ["Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas"], "prefix": "10.1038", "volume": "5", "author": [{"given": "Omar", "family": "Khan", "sequence": "first", "affiliation": []}, {"given": "Nicholas B", "family": "La Thangue", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2008, 10, 7]]}, "reference": [{"key": "BFncponc1238_CR1", "doi-asserted-by": "publisher", "first-page": "3215", "DOI": "10.1101/gad.1464906", "volume": "20", "author": "AH Ting", "year": "2006", "unstructured": "Ting AH  et al. (2006) The cancer epigenome\u2014components and functional correlates. Genes Dev 20: 3215\u20133231", "journal-title": "Genes Dev"}, {"key": "BFncponc1238_CR2", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1016/S1359-6446(05)03691-3", "volume": "11", "author": "AG Inche", "year": "2006", "unstructured": "Inche AG and La Thangue NB (2006) Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today 11: 97\u2013109", "journal-title": "Drug Discov Today"}, {"key": "BFncponc1238_CR3", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1016/j.coph.2006.03.010", "volume": "6", "author": "N Carey", "year": "2006", "unstructured": "Carey N and La Thangue NB (2006) Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 6: 369\u2013375", "journal-title": "Curr Opin Pharmacol"}, {"key": "BFncponc1238_CR4", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1038/35106079", "volume": "1", "author": "P Marks", "year": "2001", "unstructured": "Marks P  et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194\u2013202", "journal-title": "Nat Rev Cancer"}, {"key": "BFncponc1238_CR5", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.1016/S0065-230X(04)91004-4", "volume": "91", "author": "PA Marks", "year": "2004", "unstructured": "Marks PA  et al. (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137\u2013168", "journal-title": "Adv Cancer Res"}, {"key": "BFncponc1238_CR6", "doi-asserted-by": "publisher", "first-page": "84", "DOI": "10.1038/nbt1272", "volume": "25", "author": "PA Marks", "year": "2007", "unstructured": "Marks PA and Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84\u201390", "journal-title": "Nat Biotechnol"}, {"key": "BFncponc1238_CR7", "doi-asserted-by": "publisher", "first-page": "S13", "DOI": "10.1038/sj.bjc.6603465", "volume": "95", "author": "M Duvic", "year": "2006", "unstructured": "Duvic M and Zhang C (2006) Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 95: S13\u2013S19", "journal-title": "Br J Cancer"}, {"key": "BFncponc1238_CR8", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1038/38444", "volume": "389", "author": "K Luger", "year": "1997", "unstructured": "Luger K  et al. (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251\u2013260", "journal-title": "Nature"}, {"key": "BFncponc1238_CR9", "doi-asserted-by": "publisher", "first-page": "1074", "DOI": "10.1126/science.1063127", "volume": "293", "author": "T Jenuwein", "year": "2001", "unstructured": "Jenuwein T and Allis CD (2001) Translating the histone code. Science 293: 1074\u20131080", "journal-title": "Science"}, {"key": "BFncponc1238_CR10", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.1172/JCI0216547", "volume": "110", "author": "HT Spotswood", "year": "2002", "unstructured": "Spotswood HT and Turner BM (2002) An increasingly complex code. J Clin Invest 110: 577\u2013582", "journal-title": "J Clin Invest"}, {"key": "BFncponc1238_CR11", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1038/35083062", "volume": "3", "author": "HM Chan", "year": "2001", "unstructured": "Chan HM  et al. (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667\u2013674", "journal-title": "Nat Cell Biol"}, {"key": "BFncponc1238_CR12", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.1038/nrd2133", "volume": "5", "author": "JE Bolden", "year": "2006", "unstructured": "Bolden JE  et al. (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769\u2013784", "journal-title": "Nat Rev Drug Discov"}, {"key": "BFncponc1238_CR13", "doi-asserted-by": "publisher", "first-page": "737", "DOI": "10.1042/bj20021321", "volume": "370", "author": "AJ de Ruijter", "year": "2003", "unstructured": "de Ruijter AJ  et al. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737\u2013749", "journal-title": "Biochem J"}, {"key": "BFncponc1238_CR14", "first-page": "17174", "volume": "265", "author": "M Yoshida", "year": "1990", "unstructured": "Yoshida M  et al. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174\u201317179", "journal-title": "J Biol Chem"}, {"key": "BFncponc1238_CR15", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "MS Finnin", "year": "1999", "unstructured": "Finnin MS  et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188\u2013193", "journal-title": "Nature"}, {"key": "BFncponc1238_CR16", "first-page": "151", "volume": "2", "author": "KB Glaser", "year": "2003", "unstructured": "Glaser KB  et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151\u2013163", "journal-title": "Mol Cancer Ther"}, {"key": "BFncponc1238_CR17", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1016/S1535-6108(03)00165-X", "volume": "4", "author": "RW Johnstone", "year": "2003", "unstructured": "Johnstone RW and Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13\u201318", "journal-title": "Cancer Cell"}, {"key": "BFncponc1238_CR18", "doi-asserted-by": "publisher", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades CS  et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540\u2013545", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFncponc1238_CR19", "doi-asserted-by": "publisher", "first-page": "981", "DOI": "10.1158/1541-7786.MCR-07-0324", "volume": "5", "author": "M Dokmanovic", "year": "2007", "unstructured": "Dokmanovic M  et al. (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981\u2013989", "journal-title": "Mol Cancer Res"}, {"key": "BFncponc1238_CR20", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1016/j.molcel.2005.04.021", "volume": "18", "author": "JJ Kovacs", "year": "2005", "unstructured": "Kovacs JJ  et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601\u2013607", "journal-title": "Mol Cell"}, {"key": "BFncponc1238_CR21", "doi-asserted-by": "publisher", "first-page": "595", "DOI": "10.1016/S0092-8674(00)80521-8", "volume": "90", "author": "W Gu", "year": "1997", "unstructured": "Gu W and Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595\u2013606", "journal-title": "Cell"}, {"key": "BFncponc1238_CR22", "doi-asserted-by": "publisher", "first-page": "662", "DOI": "10.1093/emboj/19.4.662", "volume": "19", "author": "MA Martinez-Balbas", "year": "2000", "unstructured": "Martinez-Balbas MA  et al. (2000) Regulation of E2F1 activity by acetylation. EMBO J 19: 662\u2013671", "journal-title": "EMBO J"}, {"key": "BFncponc1238_CR23", "doi-asserted-by": "publisher", "first-page": "10826", "DOI": "10.1128/MCB.24.24.10826-10834.2004", "volume": "24", "author": "JH Patel", "year": "2004", "unstructured": "Patel JH  et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 24: 10826\u201310834", "journal-title": "Mol Cell Biol"}, {"key": "BFncponc1238_CR24", "doi-asserted-by": "publisher", "first-page": "6882", "DOI": "10.1128/MCB.20.18.6882-6890.2000", "volume": "20", "author": "AN Billin", "year": "2000", "unstructured": "Billin AN  et al. (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol 20: 6882\u20136890", "journal-title": "Mol Cell Biol"}, {"key": "BFncponc1238_CR25", "doi-asserted-by": "publisher", "first-page": "5271", "DOI": "10.1158/1078-0432.CCR-03-0709", "volume": "10", "author": "JH Park", "year": "2004", "unstructured": "Park JH  et al. (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10: 5271\u20135281", "journal-title": "Clin Cancer Res"}, {"key": "BFncponc1238_CR26", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1038/sj.cdd.4401567", "volume": "12", "author": "BH Huang", "year": "2005", "unstructured": "Huang BH  et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395\u2013404", "journal-title": "Cell Death Differ"}, {"key": "BFncponc1238_CR27", "doi-asserted-by": "publisher", "first-page": "1168", "DOI": "10.1093/emboj/cdg115", "volume": "22", "author": "Y Zhang", "year": "2003", "unstructured": "Zhang Y  et al. (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22: 1168\u20131179", "journal-title": "EMBO J"}, {"key": "BFncponc1238_CR28", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1016/S0092-8674(03)00939-5", "volume": "115", "author": "Y Kawaguchi", "year": "2003", "unstructured": "Kawaguchi Y  et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727\u2013738", "journal-title": "Cell"}, {"key": "BFncponc1238_CR29", "doi-asserted-by": "publisher", "first-page": "3357", "DOI": "10.1038/sj.emboj.7601210", "volume": "25", "author": "C Boyault", "year": "2006", "unstructured": "Boyault C  et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357\u20133366", "journal-title": "EMBO J"}, {"key": "BFncponc1238_CR30", "doi-asserted-by": "publisher", "first-page": "479", "DOI": "10.1016/S0092-8674(02)00861-9", "volume": "110", "author": "CL Zhang", "year": "2002", "unstructured": "Zhang CL  et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479\u2013488", "journal-title": "Cell"}, {"key": "BFncponc1238_CR31", "doi-asserted-by": "publisher", "first-page": "555", "DOI": "10.1016/j.cell.2004.10.024", "volume": "119", "author": "K Vega", "year": "2004", "unstructured": "Vega K  et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119: 555\u2013566", "journal-title": "Cell"}, {"key": "BFncponc1238_CR32", "doi-asserted-by": "publisher", "first-page": "377", "DOI": "10.1016/j.devcel.2007.02.004", "volume": "12", "author": "MA Arnold", "year": "2007", "unstructured": "Arnold MA  et al. (2007) MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 12: 377\u2013389", "journal-title": "Dev Cell"}, {"key": "BFncponc1238_CR33", "doi-asserted-by": "publisher", "first-page": "687", "DOI": "10.1016/S1074-7613(03)00109-2", "volume": "18", "author": "F Dequiedt", "year": "2003", "unstructured": "Dequiedt F  et al. (2003) HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18: 687\u2013698", "journal-title": "Immunity"}, {"key": "BFncponc1238_CR34", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.1016/S1535-6108(04)00114-X", "volume": "5", "author": "E Zhu", "year": "2004", "unstructured": "Zhu E  et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455\u2013463", "journal-title": "Cancer Cell"}, {"key": "BFncponc1238_CR35", "doi-asserted-by": "publisher", "first-page": "566", "DOI": "10.1038/ng1773", "volume": "38", "author": "S Ropero", "year": "2006", "unstructured": "Ropero S  et al. (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38: 566\u2013569", "journal-title": "Nat Genet"}, {"key": "BFncponc1238_CR36", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1038/nrc1779", "volume": "6", "author": "S Minucci", "year": "2006", "unstructured": "Minucci S and Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38\u201351", "journal-title": "Nat Rev Cancer"}, {"key": "BFncponc1238_CR37", "doi-asserted-by": "publisher", "first-page": "2259", "DOI": "10.1128/MCB.21.7.2259-2268.2001", "volume": "21", "author": "WS Wu", "year": "2001", "unstructured": "Wu WS  et al. (2001) The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259\u20132268", "journal-title": "Mol Cell Biol"}, {"key": "BFncponc1238_CR38", "doi-asserted-by": "publisher", "first-page": "3921", "DOI": "10.1073/pnas.0400380101", "volume": "101", "author": "P Reddy", "year": "2004", "unstructured": "Reddy P  et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukaemia effect. Proc Natl Acad Sci USA 101: 3921\u20133926", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFncponc1238_CR39", "doi-asserted-by": "publisher", "first-page": "1123", "DOI": "10.1182/blood-2006-04-019711", "volume": "109", "author": "JL Brogdon", "year": "2006", "unstructured": "Brogdon JL  et al. (2006) Histone deacetylase activities are required for innate immune cell control of Th1 but Th2 effector cell function. Blood 109: 1123\u20131130", "journal-title": "Blood"}, {"key": "BFncponc1238_CR40", "doi-asserted-by": "publisher", "first-page": "1299", "DOI": "10.1038/nm1652", "volume": "13", "author": "R Tao", "year": "2007", "unstructured": "Tao R  et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13: 1299\u20131307", "journal-title": "Nat Med"}, {"key": "BFncponc1238_CR41", "doi-asserted-by": "publisher", "first-page": "18030", "DOI": "10.1073/pnas.0408345102", "volume": "101", "author": "Y Shao", "year": "2004", "unstructured": "Shao Y  et al. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030\u201318035", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFncponc1238_CR42", "first-page": "7025", "volume": "61", "author": "X Yang", "year": "2001", "unstructured": "Yang X  et al. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61: 7025\u20137029", "journal-title": "Cancer Res"}, {"key": "BFncponc1238_CR43", "first-page": "2", "volume": "61", "author": "FF Ferrara", "year": "2001", "unstructured": "Ferrara FF  et al. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2\u20137", "journal-title": "Cancer Res"}, {"key": "BFncponc1238_CR44", "first-page": "8420", "volume": "63", "author": "M Rahmani", "year": "2003", "unstructured": "Rahmani M  et al. (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63: 8420\u20138427", "journal-title": "Cancer Res"}, {"key": "BFncponc1238_CR45", "doi-asserted-by": "publisher", "first-page": "8567", "DOI": "10.1073/pnas.0503221102", "volume": "102", "author": "T Hideshima", "year": "2005", "unstructured": "Hideshima T  et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567\u20138572", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFncponc1238_CR46", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.1007/s00280-006-0374-7", "volume": "60", "author": "A Tumber", "year": "2007", "unstructured": "Tumber A  et al. (2007) The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60: 275\u2013283", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "BFncponc1238_CR47", "doi-asserted-by": "publisher", "first-page": "223", "DOI": "10.1002/jcb.20045", "volume": "92", "author": "DC Marchion", "year": "2004", "unstructured": "Marchion DC  et al. (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223\u2013237", "journal-title": "J Cell Biochem"}, {"key": "BFncponc1238_CR48", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1038/nrd2227", "volume": "6", "author": "S Grant", "year": "2007", "unstructured": "Grant S  et al. (2007) Vorinostat. Nat Rev Drug Discov 6: 21\u201322", "journal-title": "Nat Rev Drug Discov"}, {"key": "BFncponc1238_CR49", "doi-asserted-by": "publisher", "first-page": "659", "DOI": "10.1016/j.bcp.2007.04.007", "volume": "74", "author": "KB Glaser", "year": "2007", "unstructured": "Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659\u2013671", "journal-title": "Biochem Pharmacol"}, {"key": "BFncponc1238_CR50", "doi-asserted-by": "publisher", "first-page": "102", "DOI": "10.1177/107327480701400203", "volume": "14", "author": "CA Keehn", "year": "2007", "unstructured": "Keehn CA  et al. (2007) The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control 14: 102\u2013111", "journal-title": "Cancer Control"}, {"key": "BFncponc1238_CR51", "doi-asserted-by": "publisher", "first-page": "254", "DOI": "10.1016/0190-9622(90)70208-Y", "volume": "23", "author": "TY Chuang", "year": "1990", "unstructured": "Chuang TY  et al. (1990) Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol 23: 254\u2013256", "journal-title": "J Am Acad Dermatol"}, {"key": "BFncponc1238_CR52", "doi-asserted-by": "publisher", "first-page": "3768", "DOI": "10.1182/blood-2004-09-3502", "volume": "105", "author": "R Willemze", "year": "2005", "unstructured": "Willemze R  et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768\u20133785", "journal-title": "Blood"}, {"key": "BFncponc1238_CR53", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1016/S0733-8635(18)30172-4", "volume": "12", "author": "SR Lessin", "year": "1994", "unstructured": "Lessin SR  et al. (1994) Retroviruses and cutaneous T-cell lymphoma. Dermatol Clin 12: 243\u2013253", "journal-title": "Dermatol Clin"}, {"key": "BFncponc1238_CR54", "doi-asserted-by": "publisher", "first-page": "376", "DOI": "10.1007/s11912-006-0061-1", "volume": "8", "author": "EJ Kim", "year": "2006", "unstructured": "Kim EJ  et al. (2006) Mycosis fungoides and S\u00e9zary syndrome: an update. Curr Oncol Rep 8: 376\u2013386", "journal-title": "Curr Oncol Rep"}, {"key": "BFncponc1238_CR55", "first-page": "5389", "volume": "62", "author": "R van Doorn", "year": "2002", "unstructured": "van Doorn R  et al. (2002) A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62: 5389\u20135392", "journal-title": "Cancer Res"}, {"key": "BFncponc1238_CR56", "doi-asserted-by": "publisher", "first-page": "1288", "DOI": "10.1038/sj.leu.2403385", "volume": "18", "author": "VH Sommer", "year": "2004", "unstructured": "Sommer VH  et al. (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma: evidence for an antiapoptotic function of STAT3. Leukemia 18: 1288\u20131295", "journal-title": "Leukemia"}, {"key": "BFncponc1238_CR57", "doi-asserted-by": "publisher", "first-page": "32", "DOI": "10.1111/j.1365-2133.1995.tb02488.x", "volume": "133", "author": "AF Lauritzen", "year": "1995", "unstructured": "Lauritzen AF  et al. (1995) p53 protein expression in cutaneous T-cell lymphomas. Br J Dermatol 133: 32\u201336", "journal-title": "Br J Dermatol"}, {"key": "BFncponc1238_CR58", "doi-asserted-by": "publisher", "first-page": "1565", "DOI": "10.1016/S0002-9440(10)65028-6", "volume": "156", "author": "IC Navas", "year": "2000", "unstructured": "Navas IC  et al. (2000) p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 156: 1565\u20131572", "journal-title": "Am J Pathol"}, {"key": "BFncponc1238_CR59", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1046/j.0022-202x.2001.01682.x", "volume": "118", "author": "JJ Scarisbrick", "year": "2002", "unstructured": "Scarisbrick JJ  et al. (2002) Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and S\u00e9zary syndrome. J Invest Dermatol 118: 493\u2013499", "journal-title": "J Invest Dermatol"}, {"key": "BFncponc1238_CR60", "doi-asserted-by": "publisher", "first-page": "894", "DOI": "10.1046/j.1523-1747.2003.12496.x", "volume": "121", "author": "JJ Scarisbrick", "year": "2003", "unstructured": "Scarisbrick JJ  et al. (2003) Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 121: 894\u2013901", "journal-title": "J Invest Dermatol"}, {"key": "BFncponc1238_CR61", "doi-asserted-by": "publisher", "first-page": "995", "DOI": "10.1016/j.humpath.2006.10.021", "volume": "38", "author": "C Zhang", "year": "2007", "unstructured": "Zhang C  et al. (2007) Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and S\u00e9zary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol 38: 995\u20131002", "journal-title": "Hum Pathol"}, {"key": "BFncponc1238_CR62", "doi-asserted-by": "publisher", "first-page": "1501", "DOI": "10.1101/gad.13.12.1501", "volume": "13", "author": "CJ Sherr", "year": "1999", "unstructured": "Sherr CJ and Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501\u20131512", "journal-title": "Genes Dev"}, {"key": "BFncponc1238_CR63", "doi-asserted-by": "publisher", "first-page": "3886", "DOI": "10.1200/JCO.2005.11.353", "volume": "23", "author": "R van Doorn", "year": "2005", "unstructured": "van Doorn R  et al. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23: 3886\u20133896", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR64", "doi-asserted-by": "publisher", "first-page": "503", "DOI": "10.1038/35000501", "volume": "403", "author": "AA Alizadeh", "year": "2000", "unstructured": "Alizadeh AA  et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503\u2013511", "journal-title": "Nature"}, {"key": "BFncponc1238_CR65", "doi-asserted-by": "publisher", "first-page": "15", "DOI": "10.1002/ijc.10618", "volume": "102", "author": "B Martinez-Delgado", "year": "2002", "unstructured": "Martinez-Delgado B  et al. (2002) Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 102: 15\u201319", "journal-title": "Int J Cancer"}, {"key": "BFncponc1238_CR66", "doi-asserted-by": "publisher", "first-page": "70", "DOI": "10.1046/j.1365-2141.2003.04396.x", "volume": "122", "author": "LL Siu", "year": "2003", "unstructured": "Siu LL  et al. (2003) Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 122: 70\u201377", "journal-title": "Br J Haematol"}, {"key": "BFncponc1238_CR67", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.1016/S0268-960X(03)00004-3", "volume": "17", "author": "C Querfeld", "year": "2003", "unstructured": "Querfeld C  et al. (2003) Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 17: 131\u2013142", "journal-title": "Blood Rev"}, {"key": "BFncponc1238_CR68", "first-page": "725", "volume": "63", "author": "PA Bunn Jr", "year": "1979", "unstructured": "Bunn PA Jr and Lamberg SI (1979) Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63: 725\u2013728", "journal-title": "Cancer Treat Rep"}, {"key": "BFncponc1238_CR69", "doi-asserted-by": "publisher", "first-page": "372", "DOI": "10.7326/0003-4819-109-5-372", "volume": "109", "author": "EA Sausville", "year": "1988", "unstructured": "Sausville EA  et al. (1988) Histopathologic staging at initial diagnosis of mycosis fungoides and the S\u00e9zary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 109: 372\u2013382", "journal-title": "Ann Intern Med"}, {"key": "BFncponc1238_CR70", "doi-asserted-by": "publisher", "first-page": "1014", "DOI": "10.1016/j.ejca.2006.01.025", "volume": "42", "author": "F Trautinger", "year": "2006", "unstructured": "Trautinger F  et al. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/S\u00e9zary syndrome. Eur J Cancer 42: 1014\u20131030", "journal-title": "Eur J Cancer"}, {"key": "BFncponc1238_CR71", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1001/archderm.141.3.315", "volume": "141", "author": "JB Budgin", "year": "2005", "unstructured": "Budgin JB  et al. (2005) Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 141: 315\u2013321", "journal-title": "Arch Dermatol"}, {"key": "BFncponc1238_CR72", "first-page": "1234", "volume": "8", "author": "C Zhang", "year": "2002", "unstructured": "Zhang C  et al. (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8: 1234\u20131240", "journal-title": "Clin Cancer Res"}, {"key": "BFncponc1238_CR73", "doi-asserted-by": "publisher", "first-page": "2456", "DOI": "10.1200/JCO.2001.19.9.2456", "volume": "19", "author": "M Duvic", "year": "2001", "unstructured": "Duvic M  et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19: 2456\u20132471", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR74", "first-page": "12077", "volume": "268", "author": "JC vanderSpek", "year": "1993", "unstructured": "vanderSpek JC  et al. (1993) Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin: the amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem 268: 12077\u201312082", "journal-title": "J Biol Chem"}, {"key": "BFncponc1238_CR75", "doi-asserted-by": "publisher", "first-page": "298", "DOI": "10.3816/CLM.2001.n.005", "volume": "1", "author": "FM Foss", "year": "2001", "unstructured": "Foss FM  et al. (2001) Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 1: 298\u2013302", "journal-title": "Clin Lymphoma"}, {"key": "BFncponc1238_CR76", "doi-asserted-by": "publisher", "first-page": "376", "DOI": "10.1200/JCO.2001.19.2.376", "volume": "19", "author": "E Olsen", "year": "2001", "unstructured": "Olsen E  et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19: 376\u2013388", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR77", "doi-asserted-by": "publisher", "first-page": "798", "DOI": "10.1172/JCI24826", "volume": "115", "author": "EJ Kim", "year": "2005", "unstructured": "Kim EJ  et al. (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115: 798\u2013812", "journal-title": "J Clin Invest"}, {"key": "BFncponc1238_CR78", "doi-asserted-by": "publisher", "first-page": "2318", "DOI": "10.1158/1078-0432.CCR-06-2672", "volume": "13", "author": "BS Mann", "year": "2007", "unstructured": "Mann BS  et al. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13: 2318\u20132322", "journal-title": "Clin Cancer Res"}, {"key": "BFncponc1238_CR79", "doi-asserted-by": "publisher", "first-page": "2865", "DOI": "10.1182/blood.V98.9.2865", "volume": "98", "author": "RL Piekarz", "year": "2001", "unstructured": "Piekarz RL  et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865\u20132868", "journal-title": "Blood"}, {"key": "BFncponc1238_CR80", "doi-asserted-by": "publisher", "first-page": "3923", "DOI": "10.1200/JCO.2005.14.167", "volume": "23", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly WK  et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923\u20133931", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR81", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1200/JCO.2005.01.9679", "volume": "24", "author": "OA O'Connor", "year": "2006", "unstructured": "O'Connor OA  et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166\u2013173", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR82", "doi-asserted-by": "publisher", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "volume": "109", "author": "M Duvic", "year": "2007", "unstructured": "Duvic M  et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31\u201339", "journal-title": "Blood"}, {"key": "BFncponc1238_CR83", "doi-asserted-by": "publisher", "first-page": "3109", "DOI": "10.1200/JCO.2006.10.2434", "volume": "25", "author": "EA Olsen", "year": "2007", "unstructured": "Olsen EA  et al. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109\u20133115", "journal-title": "J Clin Oncol"}, {"issue": "Suppl", "key": "BFncponc1238_CR84", "first-page": "18044", "volume": "25", "author": "AM Traynor", "year": "2007", "unstructured": "Traynor AM  et al. (2007) A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 25 (Suppl): 18044", "journal-title": "J Clin Oncol"}, {"issue": "Suppl", "key": "BFncponc1238_CR85", "first-page": "2004", "volume": "25", "author": "E Galanis", "year": "2007", "unstructured": "Galanis E  et al. (2007) N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 25 (Suppl): 2004", "journal-title": "J Clin Oncol"}, {"issue": "Suppl", "key": "BFncponc1238_CR86", "first-page": "5132", "volume": "25", "author": "M Hussain", "year": "2007", "unstructured": "Hussain M  et al. (2007) Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862). J Clin Oncol 25 (Suppl): 5132", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR87", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.3816/CLC.2006.n.003", "volume": "7", "author": "LM Krug", "year": "2006", "unstructured": "Krug LM  et al. (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7: 257\u2013261", "journal-title": "Clin Lung Cancer"}, {"issue": "Suppl", "key": "BFncponc1238_CR88", "first-page": "8027", "volume": "25", "author": "R Piekarz", "year": "2007", "unstructured": "Piekarz R  et al. (2007) Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J Clin Oncol 25 (Suppl): 8027", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR89", "first-page": "699a", "volume": "108", "author": "A Lerner", "year": "2006", "unstructured": "Lerner A  et al. (2006) Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: interim report of a phase II multicenter study [abstract #2468]. Blood 108: 699a", "journal-title": "Blood"}, {"issue": "Suppl", "key": "BFncponc1238_CR90", "first-page": "15507", "volume": "25", "author": "C Parker", "year": "2007", "unstructured": "Parker C  et al. (2007) Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 25 (Suppl): 15507", "journal-title": "J Clin Oncol"}, {"issue": "Suppl", "key": "BFncponc1238_CR91", "first-page": "14554", "volume": "24", "author": "R Molife", "year": "2006", "unstructured": "Molife R  et al. (2006) Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 24 (Suppl): 14554", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR92", "unstructured": "Sullivan D  et al. (2006) A phase II study of PXD101 in advanced multiple myeloma [poster 3583]. Presented at the American Society of Hematology Annual Meeting: 2006 December 10\u201313, Orlando, FL"}, {"key": "BFncponc1238_CR93", "unstructured": "Prince M  et al. (2006) LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T cell lymphoma (CTCL): skin expression profiles in the first 24 h related to clinical response following therapy [abstract #2715]. Blood 108 (ASH Meeting Abstracts)"}, {"issue": "Suppl", "key": "BFncponc1238_CR94", "first-page": "8000", "volume": "25", "author": "A Younes", "year": "2007", "unstructured": "Younes A  et al. (2007) A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 25 (Suppl): 8000", "journal-title": "J Clin Oncol"}, {"key": "BFncponc1238_CR95", "unstructured": "Methylgene (online 21 August 2007) Methylgene and Pharmion announce US orphan drug designation granted for mgcd0103 for the treatment of Hodgkin's lymphoma [\n                    http://www.methylgene.com/content.asp?node=267\n                    \n                  ] (accessed 13 February 2008)"}, {"key": "BFncponc1238_CR96", "doi-asserted-by": "publisher", "first-page": "1045", "DOI": "10.1111/j.0022-202X.2005.23925.x", "volume": "125", "author": "C Zhang", "year": "2005", "unstructured": "Zhang C  et al. (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125: 1045\u20131052", "journal-title": "J Invest Dermatol"}, {"key": "BFncponc1238_CR97", "doi-asserted-by": "publisher", "first-page": "3085", "DOI": "10.1158/1535-7163.MCT-06-0419", "volume": "5", "author": "JH Lee", "year": "2006", "unstructured": "Lee JH  et al. (2006) Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 5: 3085\u20133095", "journal-title": "Mol Cancer Ther"}, {"key": "BFncponc1238_CR98", "doi-asserted-by": "publisher", "first-page": "1356", "DOI": "10.1182/blood.V99.4.1356", "volume": "99", "author": "DC Zhou", "year": "2002", "unstructured": "Zhou DC  et al. (2002) Frequent mutations in the ligand-binding domain of PML-RAR alpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99: 1356\u20131363", "journal-title": "Blood"}, {"key": "BFncponc1238_CR99", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1517/17425255.2.2.213", "volume": "2", "author": "EJ Chung", "year": "2006", "unstructured": "Chung EJ  et al. (2006) Assays for pharmacodynamic analysis of histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2: 213\u2013230", "journal-title": "Expert Opin Drug Metab Toxicol"}], "container-title": ["Nature Clinical Practice Oncology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/ncponc1238.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/ncponc1238", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/ncponc1238.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T12:11:14Z", "timestamp": 1557403874000}, "score": 22.121058, "issued": {"date-parts": [[2008, 10, 7]]}, "references-count": 99, "journal-issue": {"published-print": {"date-parts": [[2008, 12]]}, "issue": "12"}, "alternative-id": ["BFncponc1238"], "URL": "http://dx.doi.org/10.1038/ncponc1238", "relation": {"cites": []}, "ISSN": ["1743-4254", "1743-4262"], "issn-type": [{"value": "1743-4254", "type": "print"}, {"value": "1743-4262", "type": "electronic"}], "subject": ["Oncology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T16:57:20Z", "timestamp": 1574787440375}, "reference-count": 71, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 4, 20]], "date-time": "2016-04-20T00:00:00Z", "timestamp": 1461110400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Int J Hematol"], "published-print": {"date-parts": [[2016, 9]]}, "DOI": "10.1007/s12185-016-2008-0", "type": "journal-article", "created": {"date-parts": [[2016, 4, 20]], "date-time": "2016-04-20T08:17:44Z", "timestamp": 1461140264000}, "page": "300-309", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Histone deacetylase inhibitors in multiple myeloma: from bench to bedside"], "prefix": "10.1007", "volume": "104", "author": [{"given": "Takeshi", "family": "Harada", "sequence": "first", "affiliation": []}, {"given": "Teru", "family": "Hideshima", "sequence": "additional", "affiliation": []}, {"given": "Kenneth C.", "family": "Anderson", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 4, 20]]}, "reference": [{"key": "2008_CR1", "doi-asserted-by": "crossref", "first-page": "1046", "DOI": "10.1056/NEJMra1011442", "volume": "364", "author": "A Palumbo", "year": "2011", "unstructured": "Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.", "journal-title": "N Engl J Med"}, {"key": "2008_CR2", "doi-asserted-by": "crossref", "first-page": "e538", "DOI": "10.1016/S1470-2045(14)70442-5", "volume": "15", "author": "SV Rajkumar", "year": "2014", "unstructured": "Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.", "journal-title": "Lancet Oncol"}, {"key": "2008_CR3", "doi-asserted-by": "crossref", "first-page": "5412", "DOI": "10.1182/blood-2008-12-194241", "volume": "113", "author": "O Landgren", "year": "2009", "unstructured": "Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137.", "journal-title": "Blood"}, {"key": "2008_CR4", "doi-asserted-by": "crossref", "first-page": "5418", "DOI": "10.1182/blood-2008-12-195008", "volume": "113", "author": "BM Weiss", "year": "2009", "unstructured": "Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418\u201322.", "journal-title": "Blood"}, {"key": "2008_CR5", "doi-asserted-by": "crossref", "first-page": "335", "DOI": "10.1038/nrc3257", "volume": "12", "author": "GJ Morgan", "year": "2012", "unstructured": "Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335\u201348.", "journal-title": "Nat Rev Cancer"}, {"key": "2008_CR6", "doi-asserted-by": "crossref", "first-page": "2516", "DOI": "10.1182/blood-2007-10-116129", "volume": "111", "author": "SK Kumar", "year": "2008", "unstructured": "Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.", "journal-title": "Blood"}, {"key": "2008_CR7", "doi-asserted-by": "crossref", "first-page": "3025", "DOI": "10.1182/blood-2010-09-307645", "volume": "117", "author": "F Gay", "year": "2011", "unstructured": "Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025\u201331.", "journal-title": "Blood"}, {"key": "2008_CR8", "doi-asserted-by": "crossref", "first-page": "673", "DOI": "10.1038/nrd4360", "volume": "13", "author": "KJ Falkenberg", "year": "2014", "unstructured": "Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673\u201391.", "journal-title": "Nat Rev Drug Discov."}, {"key": "2008_CR9", "unstructured": "Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28:525\u201342.", "DOI": "10.1038/leu.2013.350", "doi-asserted-by": "crossref"}, {"key": "2008_CR10", "doi-asserted-by": "crossref", "first-page": "12", "DOI": "10.1016/j.cell.2012.06.013", "volume": "150", "author": "MA Dawson", "year": "2012", "unstructured": "Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12\u201327.", "journal-title": "Cell"}, {"key": "2008_CR11", "doi-asserted-by": "crossref", "first-page": "1176", "DOI": "10.1093/emboj/19.6.1176", "volume": "19", "author": "T Kouzarides", "year": "2000", "unstructured": "Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000;19:1176\u20139.", "journal-title": "EMBO J"}, {"key": "2008_CR12", "doi-asserted-by": "crossref", "first-page": "1076", "DOI": "10.1002/bies.20104", "volume": "26", "author": "XJ Yang", "year": "2004", "unstructured": "Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. BioEssays. 2004;26:1076\u201387.", "journal-title": "BioEssays"}, {"key": "2008_CR13", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1016/j.jmb.2004.02.006", "volume": "338", "author": "IV Gregoretti", "year": "2004", "unstructured": "Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17\u201331.", "journal-title": "J Mol Biol"}, {"key": "2008_CR14", "doi-asserted-by": "crossref", "first-page": "284", "DOI": "10.1038/nrm2145", "volume": "8", "author": "KK Lee", "year": "2007", "unstructured": "Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn\u2019t fit all. Nat Rev Mol Cell Biol. 2007;8:284\u201395.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "2008_CR15", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1146/annurev.biochem.76.052705.162114", "volume": "76", "author": "MD Shahbazian", "year": "2007", "unstructured": "Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75\u2013100.", "journal-title": "Annu Rev Biochem"}, {"key": "2008_CR16", "doi-asserted-by": "crossref", "first-page": "834", "DOI": "10.1126/science.1175371", "volume": "325", "author": "C Choudhary", "year": "2009", "unstructured": "Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834\u201340.", "journal-title": "Science"}, {"key": "2008_CR17", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.1172/JCI69738", "volume": "124", "author": "AC West", "year": "2014", "unstructured": "West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30\u20139.", "journal-title": "J Clin Invest"}, {"key": "2008_CR18", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1038/nrd2133", "volume": "5", "author": "JE Bolden", "year": "2006", "unstructured": "Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769\u201384.", "journal-title": "Nat Rev Drug Discov"}, {"key": "2008_CR19", "doi-asserted-by": "crossref", "first-page": "1002", "DOI": "10.1016/j.chembiol.2008.09.009", "volume": "15", "author": "BC Smith", "year": "2008", "unstructured": "Smith BC, Hallows WC, Denu JM. Mechanisms and molecular probes of sirtuins. Chem Biol. 2008;15:1002\u201313.", "journal-title": "Chem Biol"}, {"key": "2008_CR20", "doi-asserted-by": "crossref", "first-page": "286", "DOI": "10.1016/S0168-9525(03)00073-8", "volume": "19", "author": "E Verdin", "year": "2003", "unstructured": "Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286\u201393.", "journal-title": "Trends Genet"}, {"key": "2008_CR21", "doi-asserted-by": "crossref", "first-page": "5450", "DOI": "10.1038/sj.onc.1210613", "volume": "26", "author": "M Martin", "year": "2007", "unstructured": "Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene. 2007;26:5450\u201367.", "journal-title": "Oncogene"}, {"key": "2008_CR22", "doi-asserted-by": "crossref", "first-page": "454", "DOI": "10.1016/j.coph.2010.04.004", "volume": "10", "author": "M Parra", "year": "2010", "unstructured": "Parra M, Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol. 2010;10:454\u201360.", "journal-title": "Curr Opin Pharmacol"}, {"key": "2008_CR23", "doi-asserted-by": "crossref", "first-page": "324", "DOI": "10.1007/s12185-013-1290-3", "volume": "97", "author": "T Hideshima", "year": "2013", "unstructured": "Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol. 2013;97:324\u201332.", "journal-title": "Int J Hematol"}, {"key": "2008_CR24", "doi-asserted-by": "crossref", "first-page": "238", "DOI": "10.1038/nchembio.313", "volume": "6", "author": "JE Bradner", "year": "2010", "unstructured": "Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6:238\u201343.", "journal-title": "Nat Chem Biol"}, {"key": "2008_CR25", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1016/j.canlet.2009.02.019", "volume": "280", "author": "P Atadja", "year": "2009", "unstructured": "Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280:233\u201341.", "journal-title": "Cancer Lett"}, {"key": "2008_CR26", "doi-asserted-by": "crossref", "first-page": "2615", "DOI": "10.1182/blood-2003-01-0233", "volume": "102", "author": "L Catley", "year": "2003", "unstructured": "Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615\u201322.", "journal-title": "Blood"}, {"key": "2008_CR27", "doi-asserted-by": "crossref", "first-page": "4055", "DOI": "10.1182/blood-2002-11-3514", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055\u201362.", "journal-title": "Blood"}, {"key": "2008_CR28", "doi-asserted-by": "crossref", "first-page": "156", "DOI": "10.1111/j.1365-2141.2004.04882.x", "volume": "125", "author": "SB Khan", "year": "2004", "unstructured": "Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125:156\u201361.", "journal-title": "Br J Haematol"}, {"key": "2008_CR29", "doi-asserted-by": "crossref", "first-page": "5781", "DOI": "10.1158/0008-5472.CAN-05-4186", "volume": "66", "author": "P Maiso", "year": "2006", "unstructured": "Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66:5781\u20139.", "journal-title": "Cancer Res"}, {"key": "2008_CR30", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1111/j.1365-2141.2007.06772.x", "volume": "139", "author": "R Feng", "year": "2007", "unstructured": "Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007;139:385\u201397.", "journal-title": "Br J Haematol"}, {"key": "2008_CR31", "doi-asserted-by": "crossref", "first-page": "646", "DOI": "10.1593/neo.04655", "volume": "7", "author": "TE Fandy", "year": "2005", "unstructured": "Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia. 2005;7:646\u201357.", "journal-title": "Neoplasia."}, {"key": "2008_CR32", "doi-asserted-by": "crossref", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "volume": "101", "author": "CS Mitsiades", "year": "2004", "unstructured": "Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540\u20135.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2008_CR33", "doi-asserted-by": "crossref", "first-page": "794", "DOI": "10.3324/haematol.2009.015495", "volume": "95", "author": "EM Ocio", "year": "2010", "unstructured": "Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95:794\u2013803.", "journal-title": "Haematologica"}, {"key": "2008_CR34", "doi-asserted-by": "crossref", "first-page": "373", "DOI": "10.1016/j.leukres.2010.06.026", "volume": "35", "author": "E Sanchez", "year": "2011", "unstructured": "Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res. 2011;35:373\u20139.", "journal-title": "Leuk Res"}, {"key": "2008_CR35", "doi-asserted-by": "crossref", "first-page": "336", "DOI": "10.1002/cncr.25584", "volume": "117", "author": "R Niesvizky", "year": "2011", "unstructured": "Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336\u201342.", "journal-title": "Cancer"}, {"key": "2008_CR36", "doi-asserted-by": "crossref", "first-page": "502", "DOI": "10.1080/10428190701817258", "volume": "49", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502\u20137.", "journal-title": "Leuk Lymphoma"}, {"key": "2008_CR37", "doi-asserted-by": "crossref", "first-page": "1820", "DOI": "10.3109/10428194.2012.661175", "volume": "53", "author": "JL Wolf", "year": "2012", "unstructured": "Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1820\u20133.", "journal-title": "Leuk Lymphoma"}, {"key": "2008_CR38", "doi-asserted-by": "crossref", "first-page": "5250", "DOI": "10.1158/1078-0432.CCR-08-2850", "volume": "15", "author": "A Badros", "year": "2009", "unstructured": "Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15:5250\u20137.", "journal-title": "Clin Cancer Res"}, {"key": "2008_CR39", "doi-asserted-by": "crossref", "first-page": "319", "DOI": "10.1016/j.clml.2012.07.007", "volume": "12", "author": "DM Weber", "year": "2012", "unstructured": "Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12:319\u201324.", "journal-title": "Clin Lymphoma Myeloma Leuk"}, {"key": "2008_CR40", "doi-asserted-by": "crossref", "first-page": "480", "DOI": "10.1182/blood-2011-03-341438", "volume": "118", "author": "DS Siegel", "year": "2011", "unstructured": "Siegel DS, Dimopoulos MA, Yoon S-S, Laubach JP, Kaufman JL, Goldschmidt H, et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood. 2011;118:480.", "journal-title": "Blood"}, {"key": "2008_CR41", "doi-asserted-by": "crossref", "first-page": "1129", "DOI": "10.1016/S1470-2045(13)70398-X", "volume": "14", "author": "M Dimopoulos", "year": "2013", "unstructured": "Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;14:1129\u201340.", "journal-title": "Lancet Oncol"}, {"key": "2008_CR42", "doi-asserted-by": "crossref", "first-page": "3696", "DOI": "10.1200/JCO.2012.46.7068", "volume": "31", "author": "JF San-Miguel", "year": "2013", "unstructured": "San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696\u2013703.", "journal-title": "J Clin Oncol"}, {"key": "2008_CR43", "doi-asserted-by": "crossref", "first-page": "2331", "DOI": "10.1182/blood-2013-01-481325", "volume": "122", "author": "PG Richardson", "year": "2013", "unstructured": "Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331\u20137.", "journal-title": "Blood"}, {"key": "2008_CR44", "doi-asserted-by": "crossref", "first-page": "1195", "DOI": "10.1016/S1470-2045(14)70440-1", "volume": "15", "author": "JF San-Miguel", "year": "2014", "unstructured": "San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195\u2013206.", "journal-title": "Lancet Oncol"}, {"key": "2008_CR45", "doi-asserted-by": "crossref", "first-page": "670", "DOI": "10.3324/haematol.2014.119735", "volume": "100", "author": "JG Berdeja", "year": "2015", "unstructured": "Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100:670\u20136.", "journal-title": "Haematologica"}, {"key": "2008_CR46", "doi-asserted-by": "crossref", "first-page": "52", "DOI": "10.1111/bjh.13517", "volume": "171", "author": "DH Vesole", "year": "2015", "unstructured": "Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, et al. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2015;171:52\u20139.", "journal-title": "Br J Haematol"}, {"key": "2008_CR47", "unstructured": "Chari A, Cho HJ, Leng S, Dhadwal A, Morgan G, La L, et al. A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. ASH Annu Meet Abstr. 2015;126:#4226."}, {"key": "2008_CR48", "doi-asserted-by": "crossref", "first-page": "1722", "DOI": "10.3109/10428194.2012.664844", "volume": "53", "author": "M Offidani", "year": "2012", "unstructured": "Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1722\u20137.", "journal-title": "Leuk Lymphoma"}, {"key": "2008_CR49", "doi-asserted-by": "crossref", "first-page": "e182", "DOI": "10.1038/bcj.2014.1", "volume": "4", "author": "DS Siegel", "year": "2014", "unstructured": "Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014;4:e182.", "journal-title": "Blood Cancer J"}, {"key": "2008_CR50", "unstructured": "Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, et al. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a phase I study. ASH Annu Meet Abstr. 2011;118:#3985."}, {"key": "2008_CR51", "doi-asserted-by": "crossref", "first-page": "8567", "DOI": "10.1073/pnas.0503221102", "volume": "102", "author": "T Hideshima", "year": "2005", "unstructured": "Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8567\u201372.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2008_CR52", "doi-asserted-by": "crossref", "first-page": "2579", "DOI": "10.1182/blood-2011-10-387365", "volume": "119", "author": "L Santo", "year": "2012", "unstructured": "Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579\u201389.", "journal-title": "Blood"}, {"key": "2008_CR53", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1111/bjh.13315", "volume": "169", "author": "Y Mishima", "year": "2015", "unstructured": "Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015;169:423\u201334.", "journal-title": "Br J Haematol"}, {"key": "2008_CR54", "doi-asserted-by": "crossref", "first-page": "406", "DOI": "10.1182/blood-2009-07-235663", "volume": "116", "author": "J Kikuchi", "year": "2010", "unstructured": "Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406\u201317.", "journal-title": "Blood"}, {"key": "2008_CR55", "doi-asserted-by": "crossref", "first-page": "680", "DOI": "10.1038/leu.2013.231", "volume": "28", "author": "J Minami", "year": "2014", "unstructured": "Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014;28:680\u20139.", "journal-title": "Leukemia"}, {"key": "2008_CR56", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1038/leu.2013.301", "volume": "28", "author": "T Hideshima", "year": "2014", "unstructured": "Hideshima T, Mazitschek R, Santo L, Mimura N, Gorgun G, Richardson PG, et al. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia. 2014;28:457\u201360.", "journal-title": "Leukemia"}, {"key": "2008_CR57", "unstructured": "Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, et al. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015;29:1918\u201327.", "DOI": "10.1038/leu.2015.83", "doi-asserted-by": "crossref"}, {"key": "2008_CR58", "doi-asserted-by": "crossref", "first-page": "8428", "DOI": "10.1038/ncomms9428", "volume": "6", "author": "SD Vallabhapurapu", "year": "2015", "unstructured": "Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, et al. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun. 2015;6:8428.", "journal-title": "Nat Commun"}, {"key": "2008_CR59", "doi-asserted-by": "crossref", "first-page": "2351", "DOI": "10.1182/blood-2012-08-445262", "volume": "120", "author": "WM Kuehl", "year": "2012", "unstructured": "Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood. 2012;120:2351\u20132.", "journal-title": "Blood"}, {"key": "2008_CR60", "doi-asserted-by": "crossref", "first-page": "2326", "DOI": "10.1038/leu.2012.119", "volume": "26", "author": "A Lopez-Girona", "year": "2012", "unstructured": "Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.", "journal-title": "Leukemia"}, {"key": "2008_CR61", "doi-asserted-by": "crossref", "first-page": "e312", "DOI": "10.1038/bcj.2015.38", "volume": "5", "author": "T Hideshima", "year": "2015", "unstructured": "Hideshima T, Cottini F, Ohguchi H, Jakubikova J, Gorgun G, Mimura N, et al. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015;5:e312.", "journal-title": "Blood Cancer J"}, {"key": "2008_CR62", "unstructured": "Raje N, Vogl DT, Hari PN, Jagannath S, Jones SS, Supko JG, et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM). ASH Annu Meet Abstr. 2013;122:#759."}, {"key": "2008_CR63", "doi-asserted-by": "crossref", "first-page": "e1134", "DOI": "10.1038/cddis.2014.98", "volume": "5", "author": "S Mithraprabhu", "year": "2014", "unstructured": "Mithraprabhu S, Khong T, Spencer A. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. Cell Death Dis. 2014;5:e1134.", "journal-title": "Cell Death Dis"}, {"key": "2008_CR64", "doi-asserted-by": "crossref", "first-page": "7237", "DOI": "10.1158/1078-0432.CCR-07-2114", "volume": "13", "author": "VR Fantin", "year": "2007", "unstructured": "Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res. 2007;13:7237\u201342.", "journal-title": "Clin Cancer Res"}, {"key": "2008_CR65", "doi-asserted-by": "crossref", "first-page": "268", "DOI": "10.1124/jpet.104.072033", "volume": "313", "author": "JJ Xiao", "year": "2005", "unstructured": "Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther. 2005;313:268\u201376.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "2008_CR66", "doi-asserted-by": "crossref", "first-page": "292", "DOI": "10.1002/ijc.10327", "volume": "99", "author": "AA Ruefli", "year": "2002", "unstructured": "Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer. 2002;99:292\u20138.", "journal-title": "Int J Cancer"}, {"key": "2008_CR67", "doi-asserted-by": "crossref", "first-page": "8071", "DOI": "10.1073/pnas.0702294104", "volume": "104", "author": "RK Lindemann", "year": "2007", "unstructured": "Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA. 2007;104:8071\u20136.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2008_CR68", "doi-asserted-by": "crossref", "first-page": "1982", "DOI": "10.1182/blood-2008-05-156851", "volume": "113", "author": "KF Whitecross", "year": "2009", "unstructured": "Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009;113:1982\u201391.", "journal-title": "Blood"}, {"key": "2008_CR69", "doi-asserted-by": "crossref", "first-page": "3785", "DOI": "10.1158/0008-5472.CAN-07-6091", "volume": "68", "author": "VR Fantin", "year": "2008", "unstructured": "Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68:3785\u201394.", "journal-title": "Cancer Res"}, {"key": "2008_CR70", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1016/j.ccr.2008.12.001", "volume": "15", "author": "S Fotheringham", "year": "2009", "unstructured": "Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009;15:57\u201366.", "journal-title": "Cancer Cell"}, {"key": "2008_CR71", "doi-asserted-by": "crossref", "first-page": "1060", "DOI": "10.1182/blood-2007-06-098061", "volume": "111", "author": "G Garcia-Manero", "year": "2008", "unstructured": "Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060\u20136.", "journal-title": "Blood"}], "container-title": ["International Journal of Hematology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s12185-016-2008-0.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s12185-016-2008-0/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12185-016-2008-0", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T05:11:31Z", "timestamp": 1559452291000}, "score": 21.774296, "issued": {"date-parts": [[2016, 4, 20]]}, "references-count": 71, "journal-issue": {"published-print": {"date-parts": [[2016, 9]]}, "issue": "3"}, "alternative-id": ["2008"], "URL": "http://dx.doi.org/10.1007/s12185-016-2008-0", "relation": {"cites": []}, "ISSN": ["0925-5710", "1865-3774"], "issn-type": [{"value": "0925-5710", "type": "print"}, {"value": "1865-3774", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T12:03:45Z", "timestamp": 1575201825008}, "reference-count": 0, "publisher": "Georg Thieme Verlag KG", "issue": "05", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Planta Med"], "DOI": "10.1055/s-0033-1336532", "type": "journal-article", "created": {"date-parts": [[2013, 3, 25]], "date-time": "2013-03-25T05:42:23Z", "timestamp": 1364190143000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Vorinostat, a Pan Histone Deacetylase Inhibitor, Stimulates Neuritic Outgrowth in PC12 Cells via Activation of MAPK and PI3K Signal Transduction Pathways"], "prefix": "10.1055", "volume": "79", "author": [{"given": "S", "family": "Shukla", "sequence": "first", "affiliation": []}, {"given": "ND", "family": "Chaurasiya", "sequence": "additional", "affiliation": []}, {"given": "LA", "family": "Walker", "sequence": "additional", "affiliation": []}, {"given": "BL", "family": "Tekwani", "sequence": "additional", "affiliation": []}], "member": "194", "published-online": {"date-parts": [[2013, 3, 22]]}, "container-title": ["Planta Medica"], "language": "en", "link": [{"URL": "http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1336532", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 5, 22]], "date-time": "2017-05-22T17:56:39Z", "timestamp": 1495475799000}, "score": 21.180254, "issued": {"date-parts": [[2013, 3, 22]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 3, 22]]}, "issue": "05"}, "URL": "http://dx.doi.org/10.1055/s-0033-1336532", "ISSN": ["0032-0943", "1439-0221"], "issn-type": [{"value": "0032-0943", "type": "print"}, {"value": "1439-0221", "type": "electronic"}], "subject": ["Organic Chemistry", "Complementary and alternative medicine", "Analytical Chemistry", "Molecular Medicine", "Pharmacology", "Drug Discovery", "Pharmaceutical Science"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:23:41Z", "timestamp": 1574133821021}, "reference-count": 0, "publisher": "Genetics Society of America", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Genetics"], "published-print": {"date-parts": [[2004, 4, 1]]}, "DOI": "10.1534/genetics.166.4.1687", "type": "journal-article", "created": {"date-parts": [[2004, 8, 2]], "date-time": "2004-08-02T23:51:28Z", "timestamp": 1091490688000}, "page": "1687-1699", "source": "Crossref", "is-referenced-by-count": 16, "title": ["The Putative RNA Helicase Dbp6p Functionally Interacts With Rpl3p, Nop8p and the Novel trans-acting Factor Rsa3p During Biogenesis of 60S Ribosomal Subunits in Saccharomyces cerevisiae"], "prefix": "10.1534", "volume": "166", "author": [{"given": "J.", "family": "de la Cruz", "sequence": "first", "affiliation": []}], "member": "414", "container-title": ["Genetics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1534/genetics.166.4.1687", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 2, 2]], "date-time": "2017-02-02T21:40:24Z", "timestamp": 1486071624000}, "score": 20.774588, "issued": {"date-parts": [[2004, 4, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2004, 4, 1]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1534/genetics.166.4.1687", "ISSN": ["0016-6731"], "issn-type": [{"value": "0016-6731", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T10:38:16Z", "timestamp": 1574764696522}, "reference-count": 92, "publisher": "Cold Spring Harbor Laboratory", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["RNA"], "published-print": {"date-parts": [[2017, 6]]}, "DOI": "10.1261/rna.060640.117", "type": "journal-article", "created": {"date-parts": [[2017, 3, 29]], "date-time": "2017-03-29T00:20:24Z", "timestamp": 1490746824000}, "page": "910-926", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Loss of the RNA helicase SKIV2L2 impairs mitotic progression and replication-dependent histone mRNA turnover in murine cell lines"], "prefix": "10.1261", "volume": "23", "author": [{"given": "Alexis M.", "family": "Onderak", "sequence": "first", "affiliation": []}, {"given": "James T.", "family": "Anderson", "sequence": "additional", "affiliation": []}], "member": "246", "published-online": {"date-parts": [[2017, 3, 28]]}, "reference": [{"key": "2018091411180621000_23.6.910.1", "DOI": "10.1101/gad.13.16.2148", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.2", "volume": "1779", "first-page": "532", "year": "2008", "article-title": "Take the \u201cA\u201d tail\u2013quality control of ribosomal and transfer RNA", "journal-title": "Biochim Biophys Acta", "DOI": "10.1016/j.bbagrm.2008.06.011", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.3", "DOI": "10.1371/journal.pgen.1003078", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.4", "DOI": "10.1261/rna.032292.112", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.5", "DOI": "10.1046/j.1432-0436.2000.660203.x", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.6", "DOI": "10.1073/pnas.1317751111", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.7", "DOI": "10.1038/nrm2184", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.8", "volume": "276", "first-page": "6177", "year": "2000", "article-title": "Three novel components of the human exosome", "journal-title": "J Biol Chem"}, {"key": "2018091411180621000_23.6.910.9", "volume": "285", "first-page": "3540", "year": "2009", "article-title": "TRAMP complex enhances RNA degradation by the nuclear exosome component Rrp6", "journal-title": "J Biol Chem"}, {"key": "2018091411180621000_23.6.910.10", "DOI": "10.1093/nar/gkm691", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.11", "DOI": "10.1371/journal.pone.0010320", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.12", "DOI": "10.1016/j.cell.2008.04.043", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.13", "DOI": "10.1038/emm.2004.66", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.14", "DOI": "10.1073/pnas.1318598111", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.15", "volume": "11", "first-page": "409", "year": "2011", "article-title": "A zebrafish SKIV2L2-enhancer trap line provides a useful tool for the study of peripheral sensory circuit development", "journal-title": "Gene Expr Patterns", "DOI": "10.1016/j.gep.2011.06.002", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.16", "DOI": "10.1128/MCB.22.3.874-885.2002", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.17", "DOI": "10.1002/cyto.990130802", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.18", "DOI": "10.1093/emboj/17.4.1128", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.19", "volume": "31", "first-page": "203", "year": "2010", "article-title": "miR-206 and -486 induce myoblast differentiation by downregulating Pax7", "journal-title": "Mol Cell Biol"}, {"key": "2018091411180621000_23.6.910.20", "volume": "12", "first-page": "1483", "year": "2015", "article-title": "Mitotic stress is an integral part of the oncogene-induced senescence program that promotes multinucleation and cell cycle arrest", "journal-title": "Cell Rep", "DOI": "10.1016/j.celrep.2015.07.055", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.21", "DOI": "10.1016/S1097-2765(03)00278-8", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.22", "volume": "15", "first-page": "153", "year": "2012", "article-title": "Stable expression of FoxA1 promotes pluripotent P19 embryonal carcinoma cells to be neural stem-like cells", "journal-title": "Gene Expr", "DOI": "10.3727/105221612X13372578119571", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.23", "volume": "9", "first-page": "e99430", "year": "2014", "article-title": "Certain adenylated non-coding RNAs, including 5\u2032 leader sequences of primary microRNA transcripts, accumulate in mouse cells following depletion of the RNA helicase MTR4", "journal-title": "PLoS One", "DOI": "10.1371/journal.pone.0099430", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.24", "DOI": "10.1016/j.cell.2008.05.031", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.25", "volume": "20", "first-page": "36", "year": "2009", "article-title": "Genome-wide mapping of SMAD target genes reveals the role of BMP signaling in embryonic stem cell fate determination", "journal-title": "Genome Res"}, {"key": "2018091411180621000_23.6.910.26", "DOI": "10.1016/j.celrep.2014.10.012", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.27", "volume": "65", "first-page": "3727", "year": "1999", "article-title": "The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities", "journal-title": "Appl Environ Microbiol"}, {"key": "2018091411180621000_23.6.910.28", "DOI": "10.1091/mbc.E08-08-0825", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.29", "volume": "34", "first-page": "157", "year": "2014", "article-title": "Effects of suppressed autophagy on mitochondrial dynamics and cell cycle of N2a cells", "journal-title": "J Huazhong Univ Sci Technol Med Sci", "DOI": "10.1007/s11596-014-1250-z", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.30", "DOI": "10.7554/eLife.02443", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.31", "DOI": "10.1021/bi301282k", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.32", "DOI": "10.1371/journal.pone.0098586", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.33", "DOI": "10.1038/nrm1964", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.34", "DOI": "10.1016/j.ydbio.2009.11.019", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.35", "DOI": "10.1182/blood-2011-09-381483", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.36", "volume": "19", "first-page": "403", "year": "2010", "article-title": "Chemical induction of cardiac differentiation in P19 embryonal carcinoma stem cells", "journal-title": "Stem Cells Dev", "DOI": "10.1089/scd.2009.0234", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.37", "DOI": "10.1073/pnas.1201085109", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.38", "DOI": "10.1038/nsmb972", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.39", "DOI": "10.1128/MCB.25.16.6879-6888.2005", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.40", "DOI": "10.1038/sj.onc.1204270", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.41", "volume": "42", "first-page": "643", "year": "2013", "article-title": "Cotranscriptional recruitment of yeast TRAMP complex to intronic sequences promotes optimal pre-mRNA splicing", "journal-title": "Nucleic Acids Res"}, {"key": "2018091411180621000_23.6.910.42", "DOI": "10.1083/jcb.66.1.188", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.43", "DOI": "10.1016/j.cell.2005.04.029", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.44", "DOI": "10.1128/MCB.22.7.2267-2282.2002", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.45", "DOI": "10.1016/S1097-2765(03)00349-6", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.46", "DOI": "10.1371/journal.pone.0064658", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.47", "volume": "27", "first-page": "306", "year": "2008", "article-title": "Cytotoxic effects of catechol to neuroblastoma N2a cells", "journal-title": "Gen Physiol Biophys"}, {"key": "2018091411180621000_23.6.910.48", "DOI": "10.1016/j.cellsig.2013.02.013", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.49", "DOI": "10.1016/j.molcel.2011.06.028", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.50", "DOI": "10.1016/j.celrep.2014.12.026", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.51", "DOI": "10.1242/jcs.047399", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.52", "DOI": "10.1038/nrg2438", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.53", "DOI": "10.1038/nature02650", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.54", "DOI": "10.1016/0092-8674(86)90483-6", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.55", "DOI": "10.1101/gad.1622708", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.56", "DOI": "10.4161/rna.19431", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.57", "DOI": "10.1038/nature08869", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.58", "volume": "14", "first-page": "1476", "year": "2009", "article-title": "Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons", "journal-title": "J Cell Mol Med", "DOI": "10.1111/j.1582-4934.2009.00916.x", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.59", "DOI": "10.1016/j.molcel.2011.08.001", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.60", "DOI": "10.1262/jrd.10-179N", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.61", "volume": "70", "first-page": "89", "year": "2012", "article-title": "Tightrope act: autophagy in stem cell renewal, differentiation, proliferation, and aging", "journal-title": "Cell Mol Life Sci"}, {"key": "2018091411180621000_23.6.910.62", "DOI": "10.1016/j.febslet.2005.12.026", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.63", "DOI": "10.1261/rna.2787011", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.64", "DOI": "10.1534/genetics.106.065987", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.65", "DOI": "10.1016/j.devcel.2004.09.002", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.66", "DOI": "10.1038/nature13537", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.67", "DOI": "10.1093/nar/gkm082", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.68", "volume": "4", "first-page": "217", "year": "2013", "article-title": "Nuclear RNA surveillance: role of TRAMP in controlling exosome specificity", "journal-title": "Wiley Interdiscip Rev RNA", "DOI": "10.1002/wrna.1155", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.69", "volume": "17", "first-page": "39", "year": "2010", "article-title": "The human cytoplasmic RNA terminal U-transferase ZCCHC11 targets histone mRNAs for degradation", "journal-title": "RNA"}, {"key": "2018091411180621000_23.6.910.70", "volume": "83", "first-page": "373", "year": "2008", "article-title": "Diazinon oxon affects the differentiation of mouse N2a neuroblastoma cells", "journal-title": "Arch Toxicol"}, {"key": "2018091411180621000_23.6.910.71", "DOI": "10.4161/cc.9.20.13636", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.72", "DOI": "10.1016/j.molcel.2014.02.027", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.73", "volume": "105", "first-page": "175", "year": "1998", "article-title": "The roles of mitotic arrest and protein synthesis in induction of apoptosis and differentiation in neuroblastoma cells in culture", "journal-title": "Dev Brain Res", "DOI": "10.1016/S0165-3806(97)00168-5", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.74", "DOI": "10.1002/yea.1899", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.75", "volume": "27", "first-page": "1345", "year": "2007", "article-title": "Histone deacetylase inhibitors induce mitotic slippage", "journal-title": "Oncogene"}, {"key": "2018091411180621000_23.6.910.76", "unstructured": "Sundaram MV . 2013. Canonical RTK-Ras-ERK signaling and related alternative pathways. WormBook, pp. 1\u201338. http://www.wormbook.org.", "DOI": "10.1895/wormbook.1.80.2", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.77", "DOI": "10.1016/j.molcel.2006.07.029", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.78", "volume": "21", "first-page": "262", "year": "2014", "article-title": "p38MAPK/MK2-mediated phosphorylation of RBM7 regulates the human nuclear exosome targeting complex", "journal-title": "RNA"}, {"key": "2018091411180621000_23.6.910.79", "DOI": "10.1016/j.jneumeth.2009.11.004", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.80", "DOI": "10.1242/jcs.154054", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.81", "volume": "14", "first-page": "107", "year": "2007", "article-title": "Degradation of hypomodified tRNAiMet in vivo involves RNA-dependent ATPase activity of the DExH helicase Mtr4p", "journal-title": "RNA", "DOI": "10.1261/rna.808608", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.82", "DOI": "10.1038/ng1969", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.83", "DOI": "10.1002/stem.1825", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.84", "DOI": "10.1073/pnas.1004953107", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.85", "volume": "51", "first-page": "1530", "year": "2015", "article-title": "Sphingomyelin synthase 1 regulates Neuro-2a cell proliferation and cell cycle progression through modulation of p27 expression and Akt signaling", "journal-title": "Mol Neurobiol", "DOI": "10.1007/s12035-014-8829-z", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.86", "DOI": "10.1074/jbc.M110.106575", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.87", "DOI": "10.1093/nar/gkq715", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.88", "DOI": "10.1371/journal.pgen.0030088", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.89", "DOI": "10.1021/bi2018255", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.90", "DOI": "10.1242/jcs.01523", "doi-asserted-by": "publisher"}, {"key": "2018091411180621000_23.6.910.91", "volume": "8", "first-page": "289", "year": "2012", "article-title": "Activated \u03b2-catenin forces N2A cell-derived neurons back to tumor-like neuroblasts and positively correlates with a risk for human neuroblastoma", "journal-title": "Int J Biol Sci", "DOI": "10.7150/ijbs.3520", "doi-asserted-by": "crossref"}, {"key": "2018091411180621000_23.6.910.92", "DOI": "10.1007/s12013-010-9148-2", "doi-asserted-by": "publisher"}], "container-title": ["RNA"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1261/rna.060640.117", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 20]], "date-time": "2019-09-20T09:09:33Z", "timestamp": 1568970573000}, "score": 20.11201, "issued": {"date-parts": [[2017, 3, 28]]}, "references-count": 92, "journal-issue": {"published-online": {"date-parts": [[2017, 5, 16]]}, "published-print": {"date-parts": [[2017, 6]]}, "issue": "6"}, "alternative-id": ["10.1261/rna.060640.117"], "URL": "http://dx.doi.org/10.1261/rna.060640.117", "relation": {"cites": []}, "ISSN": ["1355-8382", "1469-9001"], "issn-type": [{"value": "1355-8382", "type": "print"}, {"value": "1469-9001", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T04:24:50Z", "timestamp": 1574223890340}, "reference-count": 64, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 9, 1]], "date-time": "2006-09-01T00:00:00Z", "timestamp": 1157068800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Molecular Biology"], "published-print": {"date-parts": [[2006, 9]]}, "DOI": "10.1016/j.jmb.2006.07.043", "type": "journal-article", "created": {"date-parts": [[2006, 8, 1]], "date-time": "2006-08-01T15:50:10Z", "timestamp": 1154447410000}, "page": "787-799", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Translation Initiation Factor IF2 Interacts with the 30 S Ribosomal Subunit via Two Separate Binding Sites"], "prefix": "10.1016", "volume": "362", "author": [{"given": "Enrico", "family": "Caserta", "sequence": "first", "affiliation": []}, {"given": "Jerneja", "family": "Tom\u0161ic", "sequence": "additional", "affiliation": []}, {"given": "Roberto", "family": "Spurio", "sequence": "additional", "affiliation": []}, {"given": "Anna", "family": "La Teana", "sequence": "additional", "affiliation": []}, {"given": "Cynthia L.", "family": "Pon", "sequence": "additional", "affiliation": []}, {"given": "Claudio O.", "family": "Gualerzi", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Molecular Biology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0022283606009235?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0022283606009235?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 20]], "date-time": "2019-04-20T12:31:38Z", "timestamp": 1555763498000}, "score": 20.111744, "issued": {"date-parts": [[2006, 9]]}, "references-count": 64, "journal-issue": {"published-print": {"date-parts": [[2006, 9]]}, "issue": "4"}, "alternative-id": ["S0022283606009235"], "URL": "http://dx.doi.org/10.1016/j.jmb.2006.07.043", "ISSN": ["0022-2836"], "issn-type": [{"value": "0022-2836", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:39:49Z", "timestamp": 1574134789597}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Apoptosis"], "published-print": {"date-parts": [[2004, 9]]}, "DOI": "10.1023/b:appt.0000038036.31271.50", "type": "journal-article", "created": {"date-parts": [[2004, 8, 17]], "date-time": "2004-08-17T01:08:46Z", "timestamp": 1092704926000}, "page": "573-582", "source": "Crossref", "is-referenced-by-count": 68, "title": ["Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors"], "prefix": "10.1007", "volume": "9", "author": [{"given": "F.", "family": "Facchetti", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Previdi", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Ballarini", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Minucci", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Perego", "sequence": "additional", "affiliation": []}, {"given": "C. A. M. La", "family": "Porta", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Apoptosis"], "language": "en", "deposited": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T22:32:04Z", "timestamp": 1356733924000}, "score": 20.010242, "issued": {"date-parts": [[2004, 9]]}, "references-count": 0, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.1023/b:appt.0000038036.31271.50", "ISSN": ["1360-8185"], "issn-type": [{"value": "1360-8185", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T07:28:00Z", "timestamp": 1574494080792}, "reference-count": 67, "publisher": "Wiley", "issue": "9", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1484, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Devel Neurobio"], "published-print": {"date-parts": [[2011, 9]]}, "DOI": "10.1002/dneu.20878", "type": "journal-article", "created": {"date-parts": [[2011, 2, 10]], "date-time": "2011-02-10T20:44:19Z", "timestamp": 1297370659000}, "page": "759-771", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Akt1 interacts with epidermal growth factor receptors and hedgehog signaling to increase stem/transit amplifying cells in the embryonic mouse cortex"], "prefix": "10.1002", "volume": "71", "author": [{"given": "Amy", "family": "Sinor-Anderson", "sequence": "first", "affiliation": []}, {"given": "Laura", "family": "Lillien", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 8, 9]]}, "reference": [{"key": "10.1002/dneu.20878-BIB1|cit2", "doi-asserted-by": "crossref", "first-page": "683", "DOI": "10.1016/S0896-6273(04)00111-4", "article-title": "For the long run: Maintaining germinal niches in the adult brain", "volume": "41", "author": "Alvarez-Buylla", "year": "2004", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB2|cit3", "doi-asserted-by": "crossref", "first-page": "6399", "DOI": "10.1523/JNEUROSCI.23-16-06399.2003", "article-title": "Identification of a Pax6-dependent epidermal growth factor family signaling source at the lateral edge of the embryonic cerebral cortex", "volume": "23", "author": "Assimacopoulos", "year": "2003", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB3|cit4", "doi-asserted-by": "crossref", "first-page": "126", "DOI": "10.1101/gad.224503", "article-title": "Multipotent cell lineages in early mouse development depend on SOX2 function", "volume": "17", "author": "Avilion", "year": "2003", "journal-title": "Genes Dev"}, {"key": "10.1002/dneu.20878-BIB4|cit5", "doi-asserted-by": "crossref", "first-page": "657", "DOI": "10.1016/S0968-0004(01)01958-2", "article-title": "Ten years of protein kinase B signalling: A hard Akt to follow", "volume": "26", "author": "Brazil", "year": "2001", "journal-title": "Trends Biochem Sci"}, {"key": "10.1002/dneu.20878-BIB5|cit6", "first-page": "4395", "article-title": "Gli2 functions in FGF signaling during antero-posterior patterning", "volume": "127", "author": "Brewster", "year": "2000", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB6|cit7", "doi-asserted-by": "crossref", "first-page": "251", "DOI": "10.1016/S0896-6273(00)80937-X", "article-title": "Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex", "volume": "19", "author": "Burrows", "year": "1997", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB7|cit8", "first-page": "4203", "article-title": "EGFRs mediate chemotactic migration in the developing telencephalon", "volume": "128", "author": "Caric", "year": "2001", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB8|cit9", "doi-asserted-by": "crossref", "first-page": "409", "DOI": "10.1038/nn.2287", "article-title": "Proteoglycan interactions with Sonic Hedgehog specify mitogenic responses", "volume": "12", "author": "Chan", "year": "2009", "journal-title": "Nat Neurosci"}, {"key": "10.1002/dneu.20878-BIB9|cit10", "doi-asserted-by": "crossref", "first-page": "7869", "DOI": "10.1523/JNEUROSCI.18-19-07869.1998", "article-title": "Fibroblast growth factor 2 (FGF-2) promotes acquisition of epidermal growth factor (EGF) responsiveness in mouse striatal precursor cells: Identification of neural precursors responding to both EGF and FGF-2", "volume": "18", "author": "Ciccolini", "year": "1998", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB10|cit11", "doi-asserted-by": "crossref", "first-page": "5037", "DOI": "10.1523/JNEUROSCI.0715-06.2006", "article-title": "Ventral neural progenitors switch toward an oligodendroglial fate in response to increased Sonic hedgehog (Shh) activity: involvement of Sulfatase 1 in modulating Shh signaling in the ventral spinal cord", "volume": "26", "author": "Danesin", "year": "2006", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB11|cit12", "doi-asserted-by": "crossref", "first-page": "1503", "DOI": "10.1093/carcin/bgi120", "article-title": "Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells", "volume": "26", "author": "Dihlmann", "year": "2005", "journal-title": "Carcinogenesis"}, {"key": "10.1002/dneu.20878-BIB12|cit13", "doi-asserted-by": "crossref", "first-page": "543", "DOI": "10.1016/j.gde.2003.08.012", "article-title": "A niche for adult neural stem cells", "volume": "13", "author": "Doetsch", "year": "2003", "journal-title": "Curr Opin Genet Dev"}, {"key": "10.1002/dneu.20878-BIB13|cit14", "doi-asserted-by": "crossref", "first-page": "1021", "DOI": "10.1016/S0896-6273(02)01133-9", "article-title": "EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells", "volume": "36", "author": "Doetsch", "year": "2002", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB14|cit15", "doi-asserted-by": "crossref", "first-page": "540", "DOI": "10.1093/cercor/6.3.540", "article-title": "Complementary distribution of collagen type IV and the epidermal growth factor receptor in the rat embryonic telencephalon", "volume": "6", "author": "Eagleson", "year": "1996", "journal-title": "Cereb Cortex"}, {"key": "10.1002/dneu.20878-BIB15|cit16", "doi-asserted-by": "crossref", "first-page": "139", "DOI": "10.1016/j.cytogfr.2005.01.001", "article-title": "Cellular signaling by fibroblast growth factor receptors", "volume": "16", "author": "Eswarakumar", "year": "2005", "journal-title": "Cytokine Growth Factor Rev"}, {"key": "10.1002/dneu.20878-BIB16|cit17", "doi-asserted-by": "crossref", "first-page": "435", "DOI": "10.1016/S0092-8674(00)81883-8", "article-title": "PI3K: downstream AKTion blocks apoptosis", "volume": "88", "author": "Franke", "year": "1997", "journal-title": "Cell"}, {"key": "10.1002/dneu.20878-BIB17|cit18", "doi-asserted-by": "crossref", "first-page": "515", "DOI": "10.1146/annurev.cellbio.18.012502.083458", "article-title": "Regulatory principles of developmental signaling", "volume": "18", "author": "Freeman", "year": "2002", "journal-title": "Annu Rev Cell Dev Biol"}, {"key": "10.1002/dneu.20878-BIB18|cit19", "doi-asserted-by": "crossref", "first-page": "485", "DOI": "10.1016/S0896-6273(03)00637-8", "article-title": "Deregulation of dorsoventral patterning by FGF confers trilineage differentiation capacity on CNS stem cells in vitro", "volume": "40", "author": "Gabay", "year": "2003", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB19|cit20", "doi-asserted-by": "crossref", "first-page": "6309", "DOI": "10.1523/JNEUROSCI.22-15-06309.2002", "article-title": "Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage", "volume": "22", "author": "Gorski", "year": "2002", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB20|cit21", "doi-asserted-by": "crossref", "first-page": "749", "DOI": "10.1016/S0896-6273(03)00497-5", "article-title": "SOX2 functions to maintain neural progenitor identity", "volume": "39", "author": "Graham", "year": "2003", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB21|cit22", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1073/pnas.0509939103", "article-title": "PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry", "volume": "103", "author": "Groszer", "year": "2006", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB22|cit23", "doi-asserted-by": "crossref", "first-page": "2186", "DOI": "10.1126/science.1065518", "article-title": "Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo", "volume": "294", "author": "Groszer", "year": "2001", "journal-title": "Science"}, {"key": "10.1002/dneu.20878-BIB23|cit24", "doi-asserted-by": "crossref", "first-page": "28341", "DOI": "10.1074/jbc.C000352200", "article-title": "Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma", "volume": "275", "author": "Hahn", "year": "2000", "journal-title": "J Biol Chem"}, {"key": "10.1002/dneu.20878-BIB24|cit25", "first-page": "279", "article-title": "The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells", "volume": "28", "author": "Hu", "year": "2010", "journal-title": "Stem Cells"}, {"key": "10.1002/dneu.20878-BIB25|cit26", "doi-asserted-by": "crossref", "first-page": "8422", "DOI": "10.1073/pnas.0911838107", "article-title": "Transventricular delivery of Sonic hedgehog is essential to cerebellar ventricular zone development", "volume": "107", "author": "Huang", "year": "2010", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB26|cit27", "doi-asserted-by": "crossref", "first-page": "3059", "DOI": "10.1101/gad.938601", "article-title": "Hedgehog signaling in animal development: Paradigms and principles", "volume": "15", "author": "Ingham", "year": "2001", "journal-title": "Genes Dev"}, {"key": "10.1002/dneu.20878-BIB27|cit28", "doi-asserted-by": "crossref", "first-page": "400", "DOI": "10.1016/j.conb.2010.04.003", "article-title": "Stem cells niches during development-lessons from the cerebral cortex", "volume": "20", "author": "Johansson", "year": "2010", "journal-title": "Curr Opin Neurobiol"}, {"key": "10.1002/dneu.20878-BIB28|cit29", "doi-asserted-by": "crossref", "first-page": "8244", "DOI": "10.1074/jbc.M210635200", "article-title": "Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase", "volume": "278", "author": "Kanda", "year": "2003", "journal-title": "J Biol Chem"}, {"key": "10.1002/dneu.20878-BIB29|cit30", "doi-asserted-by": "crossref", "first-page": "6283", "DOI": "10.1128/MCB.02317-05", "article-title": "Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes", "volume": "26", "author": "Kasper", "year": "2006", "journal-title": "Mol Cell Biol"}, {"key": "10.1002/dneu.20878-BIB30|cit31", "doi-asserted-by": "crossref", "first-page": "1289", "DOI": "10.1242/dev.01027", "article-title": "Cooperation between sonic hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical precursors", "volume": "131", "author": "Kessaris", "year": "2004", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB31|cit32", "doi-asserted-by": "crossref", "first-page": "2717", "DOI": "10.1242/dev.015891", "article-title": "Hedgehog signaling is involved in development of the neocortex", "volume": "135", "author": "Komada", "year": "2008", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB32|cit33", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1002/(SICI)1096-9861(19970407)380:2<243::AID-CNE7>3.0.CO;2-3", "article-title": "Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain", "volume": "380", "author": "Kornblum", "year": "1997", "journal-title": "J Comp Neurol"}, {"key": "10.1002/dneu.20878-BIB33|cit34", "first-page": "i74", "article-title": "Environmental signals elicit multiple responses in dorsal telencephalic progenitors by threshold-dependent mechanisms. Cereb Cortex", "volume": "1", "author": "Lillien", "year": "2006", "journal-title": "Suppl"}, {"key": "10.1002/dneu.20878-BIB34|cit35", "first-page": "4993", "article-title": "BMP and FGF regulate the development of EGF-responsive neural progenitor cells", "volume": "127", "author": "Lillien", "year": "2000", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB35|cit36", "first-page": "5099", "article-title": "Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation", "volume": "128", "author": "Long", "year": "2001", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB36|cit37", "doi-asserted-by": "crossref", "first-page": "775", "DOI": "10.1523/JNEUROSCI.1700-08.2009", "article-title": "Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex", "volume": "29", "author": "Mairet-Coello", "year": "2009", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB37|cit38", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1016/j.bbaexp.2003.09.001", "article-title": "NF-kappaB stimulates Akt phosphorylation and gene expression by distinct signaling mechanisms", "volume": "1630", "author": "Meng", "year": "2003", "journal-title": "Biochim Biophys Acta"}, {"key": "10.1002/dneu.20878-BIB38|cit39", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1016/j.stem.2009.05.008", "article-title": "Home at last: Neural stem cell niches defined", "volume": "4", "author": "Miller", "year": "2009", "journal-title": "Cell Stem Cell"}, {"key": "10.1002/dneu.20878-BIB39|cit40", "doi-asserted-by": "crossref", "first-page": "598", "DOI": "10.1016/j.cell.2008.01.038", "article-title": "Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life", "volume": "132", "author": "Morrison", "year": "2008", "journal-title": "Cell"}, {"key": "10.1002/dneu.20878-BIB40|cit41", "doi-asserted-by": "crossref", "first-page": "30934", "DOI": "10.1074/jbc.M004112200", "article-title": "Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation", "volume": "275", "author": "Okano", "year": "2000", "journal-title": "J Biol Chem"}, {"key": "10.1002/dneu.20878-BIB41|cit42", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1242/dev.00930", "article-title": "Hedgehog-GLI signaling regulates the behavior of cells with stem cell properties in the developing neocortex", "volume": "131", "author": "Palma", "year": "2004", "journal-title": "Development"}, {"key": "10.1002/dneu.20878-BIB42|cit43", "doi-asserted-by": "crossref", "first-page": "6387", "DOI": "10.1073/pnas.0810407106", "article-title": "Simultaneous prospective purification of adult subventricular zone neural stem cells and their progeny", "volume": "106", "author": "Pastrana", "year": "2009", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB43|cit44", "doi-asserted-by": "crossref", "first-page": "1348", "DOI": "10.1002/dneu.20506", "article-title": "PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation", "volume": "67", "author": "Peltier", "year": "2007", "journal-title": "Dev Neurobiol"}, {"key": "10.1002/dneu.20878-BIB44|cit45", "doi-asserted-by": "crossref", "first-page": "81", "DOI": "10.1016/S0896-6273(01)80048-9", "article-title": "FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells", "volume": "18", "author": "Qian", "year": "1997", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB45|cit46", "doi-asserted-by": "crossref", "first-page": "1707", "DOI": "10.1126/science.1553558", "article-title": "Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system", "volume": "255", "author": "Reynolds", "year": "1992", "journal-title": "Science"}, {"key": "10.1002/dneu.20878-BIB46|cit47", "doi-asserted-by": "crossref", "first-page": "4565", "DOI": "10.1523/JNEUROSCI.12-11-04565.1992", "article-title": "A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes", "volume": "12", "author": "Reynolds", "year": "1992", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB47|cit48", "doi-asserted-by": "crossref", "first-page": "4505", "DOI": "10.1073/pnas.0504337103", "article-title": "Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling", "volume": "103", "author": "Riob\u00f3", "year": "2006a", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB48|cit49", "doi-asserted-by": "crossref", "first-page": "1612", "DOI": "10.4161/cc.5.15.3130", "article-title": "Hedgehog signal transduction: Signal integration and cross talk in development and cancer", "volume": "15", "author": "Riobo", "year": "2006b", "journal-title": "Cell Cycle"}, {"key": "10.1002/dneu.20878-BIB49|cit50", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.1016/0092-8674(95)90397-6", "article-title": "Floor plate and motor neuron induction by different concentrations of the amino-terminal cleavage product of sonic hedgehog autoproteolysis", "volume": "81", "author": "Roelink", "year": "1995", "journal-title": "Cell"}, {"key": "10.1002/dneu.20878-BIB50|cit51", "doi-asserted-by": "crossref", "first-page": "513", "DOI": "10.1016/j.gde.2003.08.005", "article-title": "The emergent design of the neural tube: Prepattern. SHH morphogen and GLI code", "volume": "13", "author": "Ruiz i Altaba", "year": "2003", "journal-title": "Curr Opin Genet Dev"}, {"key": "10.1002/dneu.20878-BIB51|cit52", "doi-asserted-by": "crossref", "first-page": "8531", "DOI": "10.1523/JNEUROSCI.1470-04.2004", "article-title": "Akt-1 expression level regulates CNS precursors", "volume": "24", "author": "Sinor", "year": "2004", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB52|cit53", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1016/S0092-8674(00)81780-8", "article-title": "Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN", "volume": "95", "author": "Stambolic", "year": "1998", "journal-title": "Cell"}, {"key": "10.1002/dneu.20878-BIB53|cit54", "doi-asserted-by": "crossref", "first-page": "5895", "DOI": "10.1073/pnas.0700776104", "article-title": "Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways", "volume": "104", "author": "Stecca", "year": "2007", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB54|cit55", "doi-asserted-by": "crossref", "first-page": "873", "DOI": "10.1016/j.neuron.2005.01.045", "article-title": "Asymmetric distribution of EGFR receptor during mitosis generates diverse CNS progenitor cells", "volume": "45", "author": "Sun", "year": "2005", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB55|cit56", "doi-asserted-by": "crossref", "first-page": "165", "DOI": "10.1634/stemcells.2008-0580", "article-title": "Gli2 is a novel regulator of sox2 expression in telencephalic neuroepithelial cells", "volume": "27", "author": "Takanaga", "year": "2009", "journal-title": "Stem Cells"}, {"key": "10.1002/dneu.20878-BIB56|cit57", "doi-asserted-by": "crossref", "first-page": "112", "DOI": "10.1038/35102174", "article-title": "The development of neural stem cells", "volume": "414", "author": "Temple", "year": "2001", "journal-title": "Nature"}, {"key": "10.1002/dneu.20878-BIB57|cit58", "author": "Theiler", "year": "1972", "volume-title": "The House Mouse"}, {"key": "10.1002/dneu.20878-BIB58|cit59", "doi-asserted-by": "crossref", "first-page": "230", "DOI": "10.1126/science.7618084", "article-title": "Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype", "volume": "269", "author": "Threadgill", "year": "1995", "journal-title": "Science"}, {"key": "10.1002/dneu.20878-BIB59|cit60", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1006/dbio.1998.9192", "article-title": "Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon", "volume": "208", "author": "Tropepe", "year": "1999", "journal-title": "Dev Biol"}, {"key": "10.1002/dneu.20878-BIB60|cit61", "doi-asserted-by": "crossref", "first-page": "561", "DOI": "10.1042/0264-6021:3460561", "article-title": "The PI3K-PDK1 connection: more than just a road to PKB", "volume": "346", "author": "Vanhaesebroeck", "year": "2000", "journal-title": "Biochem J"}, {"key": "10.1002/dneu.20878-BIB61|cit62", "doi-asserted-by": "crossref", "first-page": "5919", "DOI": "10.1523/JNEUROSCI.23-13-05919.2003", "article-title": "Wnt regulation of progenitor maturation in the cortex depends on Shh or fibroblast growth factor 2", "volume": "23", "author": "Viti", "year": "2003", "journal-title": "J Neurosci"}, {"key": "10.1002/dneu.20878-BIB62|cit63", "doi-asserted-by": "crossref", "first-page": "1427", "DOI": "10.1126/science.287.5457.1427", "article-title": "Out of Eden: Stem cells and their niches", "volume": "287", "author": "Watt", "year": "2000", "journal-title": "Science"}, {"key": "10.1002/dneu.20878-BIB63|cit64", "doi-asserted-by": "crossref", "first-page": "9255", "DOI": "10.1073/pnas.151173398", "article-title": "A role of PDGFRalpha in basal cell carcinoma proliferation", "volume": "98", "author": "Xie", "year": "2001", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/dneu.20878-BIB64|cit65", "doi-asserted-by": "crossref", "first-page": "328", "DOI": "10.1016/j.neuron.2010.01.004", "article-title": "Sonic hedgehog signaling confers ventral telencephalic progenitors with distinct cortical interneuron fates", "volume": "65", "author": "Xu", "year": "2010", "journal-title": "Neuron"}, {"key": "10.1002/dneu.20878-BIB65|cit66", "doi-asserted-by": "crossref", "first-page": "406", "DOI": "10.1038/nature07275", "article-title": "A paracrine requirement for hedgehog signalling in cancer", "volume": "455", "author": "Yauch", "year": "2008", "journal-title": "Nature"}, {"key": "10.1002/dneu.20878-BIB66|cit67", "doi-asserted-by": "crossref", "first-page": "472", "DOI": "10.1016/j.devcel.2009.12.025", "article-title": "Cortical neural precursors inhibit their own differentiation via N-cadherin maintenance of beta-catenin signaling", "volume": "18", "author": "Zhang", "year": "2010", "journal-title": "Dev Cell"}, {"key": "10.1002/dneu.20878-BIB67|cit68", "doi-asserted-by": "crossref", "first-page": "781", "DOI": "10.1016/S0092-8674(01)00385-3", "article-title": "Smoothened mutants reveal redundant roles for Shh and Ihh signaling including regulation of L/R asymmetry by the mouse node", "volume": "105", "author": "Zhang", "year": "2001", "journal-title": "Cell"}], "container-title": ["Developmental Neurobiology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fdneu.20878", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 8]], "date-time": "2019-06-08T13:40:42Z", "timestamp": 1560001242000}, "score": 19.81234, "issued": {"date-parts": [[2011, 8, 9]]}, "references-count": 67, "journal-issue": {"published-print": {"date-parts": [[2011, 9]]}, "issue": "9"}, "URL": "http://dx.doi.org/10.1002/dneu.20878", "relation": {"cites": []}, "ISSN": ["1932-8451"], "issn-type": [{"value": "1932-8451", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:05:17Z", "timestamp": 1575183917805}, "reference-count": 0, "publisher": "Bentham Science Publishers Ltd.", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CPD"], "published-print": {"date-parts": [[2012, 12, 10]]}, "DOI": "10.2174/1381612811306040734", "type": "journal-article", "created": {"date-parts": [[2013, 2, 19]], "date-time": "2013-02-19T07:02:04Z", "timestamp": 1361257324000}, "page": "734-744", "source": "Crossref", "is-referenced-by-count": 1, "title": ["New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors"], "prefix": "10.2174", "volume": "19", "author": [{"family": "Michele Cea", "sequence": "first", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Antonia Cagnetta", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Marco Gobbi", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Franco Patrone", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Paul G. Richardson", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Teru Hideshima", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}, {"family": "Kenneth C. Anderson", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115."}]}], "member": "965", "container-title": ["Current Pharmaceutical Design"], "language": "en", "link": [{"URL": "http://eurekaselect.com/article/download/105586", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 7, 12]], "date-time": "2017-07-12T07:47:12Z", "timestamp": 1499845632000}, "score": 19.775986, "issued": {"date-parts": [[2012, 12, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2012, 12, 10]]}, "issue": "4"}, "alternative-id": ["LiveAll1"], "URL": "http://dx.doi.org/10.2174/1381612811306040734", "ISSN": ["1381-6128"], "issn-type": [{"value": "1381-6128", "type": "print"}], "subject": ["Pharmacology", "Drug Discovery"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:19:00Z", "timestamp": 1575530340577}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "8", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1992, 10, 15]]}, "abstract": "<jats:p>Studies were performed to elucidate the functional significance of factor Xa interactions at the monocyte membrane in the presence and absence of factor Va, with respect to prothrombin and factor IX cleavage. Factor Xa-catalyzed prothrombin activation at the monocyte surface was absolutely dependent on the addition of factor Va, indicating that thrombin was generated solely by a membrane-bound complex of factors Va and Xa. In contrast, in the absence of added factor Va, factor Xa bound to monocytes catalyzed the cleavage of factor IX to the nonenzymatic intermediate factor IX alpha through a reaction that was dependent on both monocyte and factor Xa concentration. At limiting factor Xa concentration, added factor Va inhibited the factor Xa-catalyzed cleavage of factor IX, suggesting that a monocyte-bound complex of factors Va and Xa did not recognize factor IX as a substrate. These combined data suggest that factor Xa interacts with the monocyte through two sites which can be distinguished by their requirement for added factor Va and their expression of different functional activities. Both functional sites could be distinguished also by their differential susceptibility to inhibition by a monoclonal antibody directed against the light chain of factor Va (alpha-HFV1). At the monocyte surface, the factor Va/Xa- catalyzed activation of prothrombin was maximally inhibited with 0.25 mumol/L alpha-HFV1, whereas 1.0 mumol/L alpha-HFV1 was required to effect 50% inhibition of the factor Xa-catalyzed cleavage of factor IX. The ability of factor Va to modulate factor Xa substrate specificity was investigated further. Factor Xa bound to thrombin-activated platelets either through platelet-released factor Va or added factor Va did not cleave factor IX. Consistent with this result, a plasma concentration of factor IX had no effect on thrombin generation catalyzed by a platelet-bound complex of factors Va and Xa. In marked contrast, factor Xa bound to phospholipid vesicles either independently or in complex with factor Va catalyzed factor IX cleavage with equal efficiency. These combined data indicate that factor Va bound to cell surfaces modulates factor Xa substrate specificity, whereas no discriminatory effect is conferred by factor Va bound to phospholipid vesicles. Thus, by providing two distinct sites at its membrane surface, the monocyte modulates factor Xa binding and the functional activity expressed by the bound enzyme, depending on the availability of factor Va.</jats:p>", "DOI": "10.1182/blood.v80.8.1989.bloodjournal8081989", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T07:09:06Z", "timestamp": 1570950546000}, "page": "1989-1997", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Factor Xa interacts with two sites on monocytes with different functional activities"], "prefix": "10.1182", "volume": "80", "author": [{"given": "LA", "family": "Worfolk", "sequence": "first", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}, {"given": "RA", "family": "Robinson", "sequence": "additional", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}, {"given": "PB", "family": "Tracy", "sequence": "additional", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/80/8/1989/225544/1989.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/80/8/1989/225544/1989.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T03:55:12Z", "timestamp": 1574222112000}, "score": 19.460014, "issued": {"date-parts": [[1992, 10, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992, 10, 15]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1182/blood.v80.8.1989.bloodjournal8081989", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:25:15Z", "timestamp": 1575530715990}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "8", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1992, 10, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Studies were performed to elucidate the functional significance of factor Xa interactions at the monocyte membrane in the presence and absence of factor Va, with respect to prothrombin and factor IX cleavage. Factor Xa-catalyzed prothrombin activation at the monocyte surface was absolutely dependent on the addition of factor Va, indicating that thrombin was generated solely by a membrane-bound complex of factors Va and Xa. In contrast, in the absence of added factor Va, factor Xa bound to monocytes catalyzed the cleavage of factor IX to the nonenzymatic intermediate factor IX alpha through a reaction that was dependent on both monocyte and factor Xa concentration. At limiting factor Xa concentration, added factor Va inhibited the factor Xa-catalyzed cleavage of factor IX, suggesting that a monocyte-bound complex of factors Va and Xa did not recognize factor IX as a substrate. These combined data suggest that factor Xa interacts with the monocyte through two sites which can be distinguished by their requirement for added factor Va and their expression of different functional activities. Both functional sites could be distinguished also by their differential susceptibility to inhibition by a monoclonal antibody directed against the light chain of factor Va (alpha-HFV1). At the monocyte surface, the factor Va/Xa- catalyzed activation of prothrombin was maximally inhibited with 0.25 mumol/L alpha-HFV1, whereas 1.0 mumol/L alpha-HFV1 was required to effect 50% inhibition of the factor Xa-catalyzed cleavage of factor IX. The ability of factor Va to modulate factor Xa substrate specificity was investigated further. Factor Xa bound to thrombin-activated platelets either through platelet-released factor Va or added factor Va did not cleave factor IX. Consistent with this result, a plasma concentration of factor IX had no effect on thrombin generation catalyzed by a platelet-bound complex of factors Va and Xa. In marked contrast, factor Xa bound to phospholipid vesicles either independently or in complex with factor Va catalyzed factor IX cleavage with equal efficiency. These combined data indicate that factor Va bound to cell surfaces modulates factor Xa substrate specificity, whereas no discriminatory effect is conferred by factor Va bound to phospholipid vesicles. Thus, by providing two distinct sites at its membrane surface, the monocyte modulates factor Xa binding and the functional activity expressed by the bound enzyme, depending on the availability of factor Va.</jats:p>", "DOI": "10.1182/blood.v80.8.1989.1989", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T20:36:33Z", "timestamp": 1570998993000}, "page": "1989-1997", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Factor Xa interacts with two sites on monocytes with different functional activities"], "prefix": "10.1182", "volume": "80", "author": [{"given": "LA", "family": "Worfolk", "sequence": "first", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}, {"given": "RA", "family": "Robinson", "sequence": "additional", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}, {"given": "PB", "family": "Tracy", "sequence": "additional", "affiliation": [{"name": "Department of Cell and Molecular Biology, University of Vermont College of Medicine, Burlington 05405."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/80/8/1989/609051/1989.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/80/8/1989/609051/1989.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T07:48:38Z", "timestamp": 1574236118000}, "score": 19.460014, "issued": {"date-parts": [[1992, 10, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992, 10, 15]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1182/blood.v80.8.1989.1989", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}